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ABSTRACT
Exploration of the inhibitory properties of the nucleoside antibiotic salicyl-AMS and analogues
targeting siderophore biosynthesis in Mycobacterium tuberculosis
by
Glennon Valere Bythrow
Advisor: Dr. Luis E. N. Quadri
Mycobacterium tuberculosis (Mtb) is a resilient, obligate bacterial pathogen responsible
for pulmonary tuberculosis disease (TB), that has upheld a significant impact on global public
health throughout history. The World Health Organization (WHO) approximates nearly 10
million new TB cases arose in 2017 alone, accounting for 1.6 million deaths. There has been a
notable rise in TB cases produced by multidrug-resistant (MDR) and extensively drug-resistant
(XDR) strains of Mtb. This, along with the intrinsic resistance of Mtb to many standard drugs
and poor patient compliance, is deeply impacting global control of TB. Among the several
strategies currently in place to progressively reduce TB burden, research into the development of
novel anti-TB drugs is vital for both treatment and prevention.
In pursuit of investigating novel drugs against Mtb, the first-in-class nucleoside antibiotic
salicyl-AMS (5′-O-[N-salicylsulfamoyl]-adenosine) was characterized. Salicyl-AMS is an
inhibitor of the salicylate adenylation enzyme MbtA, required for the initial step towards
biosynthesis of the small molecule, iron-scavenging siderophore metabolites known as the
mycobactins (MBTS). Salicyl-AMS was shown to inhibit MbtA activity, diminish production of
MBTS, and display antimicrobial activity against Mtb. Though salicyl-AMS reduced the burden
of Mtb in a mouse model of infection, it demonstrated a poor pharmacological profile.
Here, we evaluated two novel salicyl-AMS analogues to further probe the structure
activity relationship (SAR), alongside salicyl-AMS and six of the most potent previously
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reported analogues, in both biochemical and cell-based studies. In pursuit of this, we optimized
the purification of a recombinant MbtA and the conditions of the continuous, spectrophotometric
HA-MesG assay to improve the methodological platform for the study of MbtA inhibition. The
new recombinant MbtA (H10MbtAopt) protein was used in conjunction with the improved HAMesG assay to determine enzyme kinetic parameters (Km and kcat) and measure the intrinsic
inhibition (Ki) by salicyl-AMS. Biochemical studies of the nine MbtA inhibitors included
app

determination of kinetic parameters (Ki , kapp
on , koff, and tR) and analysis of their mechanism of
inhibition. Additionally, we developed a non-pathogenic, fast-growing Mycobacterium
smegmatis model engineered for susceptibility to MbtA inhibitors. The model strain was
dependent on the MbtA from Mtb for production of MBTS and used to evaluate antimicrobial
properties (MIC and PAE) of the nine analogues. In all, these studies expand our understanding
of the mechanism of inhibition of MbtA by these inhibitors, expose new SAR insights into this
family of nucleoside antibiotics, and highlight several candidates for future preclinical
evaluation.
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CHAPTER 1: INTRODUCTION
MYCOBACTERIA
Mycobacterium is the only genus in the family Mycobactericeae, often referred to as the
“mycobacteria” group, though division of the family into more genetically similar genera has
recently been proposed.1 The most prominent Mycobacterium pathogens are those in the
Mycobacterium tuberculosis complex (MTBC) and Mycobacterium leprae. In addition, there are
over 150 other species of nontuberculous mycobacteria (NTM) with their own shifting degrees
of pathogenicity.1-3 Due to modern improvements in gene sequencing capabilities, this number of
NTM species continues to grow substantially.3 Significance to human disease differs among the
family and includes nonpathogenic saprophytes, opportunistic pathogens, and obligate
pathogens.3
Microscopically, mycobacteria are a non-spore forming aerobic group that appear
microscopically as straight or slightly curved rods, 1.0 – 10 µm in length and 0.2 – 0.6 µm in
width. Due to their unique cell envelope structure they do not gram stain properly, and are
instead differentiated by a positive acid-fast stain like other Actinobacteria with high mycolic
acid content outer membranes.2 Species-specific colony morphology can appear either smooth,
rough, mucoid, or dry in appearance with the presence of a yellow pigmentation depending on
their carotenoid producing capabilities.2
Mycobacterium Classification
Before modern advances in identification techniques, microbiologists in the 1950s used a
phenotypic assessment for distinction of NTM from MTBC organisms. These organisms were
classified into four Runyon groups based on their rate of growth and the conditions necessary to
produce carotenoid-based pigment (Figure 1-1).4, 5 The increasing use of molecular typing for
1

identification has diminished the need for this classification system, but the general grouping by
growth rate remains an important characteristic in preliminary identification.3 Runyon groups I,
II, and III are considered slow growing mycobacteria (SGM) due to their long duplication period,
distinguished by growth taking more than 7 days in standard media. Group IV organisms are
considered rapid growing mycobacteria (RGM), which grow in media in less than 7 days and are
further united by their inability to produce pigment.4, 5 Among the slow growing groups, Group I
is considered the photochromogens, which can produce pigment only after exposure to light.
Group II are the scotochromogens, which can produce pigment independent of light. The
nonchromagen Group III produce no carotenoid pigmentation.4, 5 MTBC organisms like
Mycobacterium tuberculosis (Mtb) are also considered slow-growers, while M. leprae is unique
in its requirement of a mammalian host for propagation, and none of these pathogens produce
carotenoid pigment.3

Figure 1-1. Division of the major mycobacteria groups.
Flowchart demonstrates division of the tuberculosis causing MTBC organisms, the NTM, and M.
leprae. Ovals demonstrate the shared growth characteristics of each division. The NTM are
broken down into the four Runyon groups based on growth rate and carotenoid pigment
production capabilities (Group I - Photochromogens; Group II – Scotochromogens; Group III –
Nonchromogens; Group IV – Rapid-growers). A representative species of each group is
indicated.
2

Further classification became necessary as the clinical importance of NTM was
recognized. A new approach was developed in the 1960s using many phenotypic characteristics
to speciate in an attempt to better understand NTM’s relevance to human disease.4 Around the
turn of the century 16S RNA sequencing was used to organize various species into groups with
highly similar nucleotide signatures, allowing for identification of evolutionarily significant
clades.4 The three main clades for RGM include the Mycobacterium fortuitum complex, the
Mycobacterium smegmatis complex, and the Mycobacterium abscessus-chelonae complex.4 The
Mycobacterium terrae complex is considered “intermediate” growers, due to their phylogenetic
positioning between the major branches RGM and SGM.4 Finally, the SGM are grouped into the
MTBC, the Mycobacterium avium complex, and the smaller Mycobacterium kansasii,
Mycobacterium celatum, Mycobacterium marinum-ulcerans, and Mycobacterium simiae groups.4

Figure 1-2. New division of the Mycobacteriaceae family into 5 independent genera.
The groupings were determined bioinformatically by phylogenetic analysis of nearly 2000 core
proteins. The new genera follow traditional classifications based on growth rate and previously
identified phylogenetic clades. The five new designations are divided in color coded boxes, and
the new genus names are bolded. Adapted from [1].
3

Recently, it was proposed that the current genus of Mycobacterium be further divided
into 5 new genera based on phylogenetic trees constructed from ~2000 core proteins and average
amino acid identities of conserved protein families.1 The five major resulting groupings closely
resembles the traditional clades previously identified by 16S RNA gene sequences, but
ultimately combines many into larger groups (Figure 1-2). The M. abscessus-chelonae complex
remains phylogenetically isolated and is now deemed the Mycobacteriodes genus. All other
RGM including M. smegmatis and M. fortuitum are now Mycolicibacterium. Most intermediate
M. terrae complex organisms are now Mycolicibacter, and three genetically unique organisms of
the M. trivale clade are now the Mycolicibacillus genus. Finally, the genus name Mycobacterium
has been conserved for all remaining SGM. This includes the MTBC, the M. avium complex, M.
leprea, and other important human pathogens.1 For the purposes of this work, the traditional
single grouping of all species as Mycobacterium will be used, as this new naming convention has
not yet permeated the field.
Identification
In the last 20 years, identification of Mycobacterium has flourished due to the widespread
adoption of techniques such as gene sequencing. Previously, identification was primarily done by
testing of biochemical characteristics, but these techniques have been abandoned due to their
inefficiencies in time and distinguishing power.6 Since 2002 more than 50 new mycobacterial
species have been discovered using molecular techniques.6
Methods for mycobacterial identification have been improving long before introduction
of gene sequencing. Many utilize the unique lipid-rich cell envelope, composed of unique and
high mycolic acid contents, for differentiation.6 More recently, use of matrix-assisted laser
desorption ionization-time of flight (MALDI-TOF) mass spectrometry has been pursued in
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clinical labs, but the difficulties with mycobacterial sample preparation remains a key assay
limitation.6 Currently, PCR restriction analysis is most used, requiring amplification of the hsp65
gene and subsequent BstEII and HaeII digestion to reveal species specific restriction profiles
after gel electrophoresis.6 Additionally, DNA probe kits allow for rapid identification of some of
the most frequently isolated species.6
Despite these advancements, gene sequencing is the strongest reference method for
mycobacterial identification. Several genes have been validated for taxonomical purposes
including the 16S rRNA gene, the hsp65 heat shock protein gene, the rpoB RNA polymerase βsubunit gene, and the sodA superoxide dismutase gene.6 When mycobacteria are poorly
distinguished by PCR restriction analysis or DNA probe kits they should be further pursued by
gene sequencing of the 16S rRNA gene and cross referenced with GenBank submissions.6
The Nontuberculous Mycobacteria (NTM):
NTM are environmental water and soil organisms, of which only some are opportunistic
human pathogens when aerosolized or contacted.2 The group can be divided into organisms that
are strictly environmental, organisms previously isolated from animals, and organisms that have
any history of being isolated from patients.6 Recently, the large majority of newly discovered
NTM have been discovered from patient samples.6
For those NTM that cause human disease, reservoirs are usually water systems and
shower heads from which the bacteria are aerosolized, and occasionally medical devices.2 Some
NTM can cause pulmonary disease reminiscent of tuberculosis but often infect lymph, skin,
bone, and joints instead.6 Person-to-person transmission is not considered to occur.6 There has
recently been two challenges to this paradigm, with evidence for person-to-person transmission
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of M. abscessus subsp. massiliense between cystic fibrosis patients. It remains unclear whether
this was respiratory droplet spread or through contamination of patients’ shared clinic space.7, 8
Mycobacterium leprae
M. leprae is separate from the MTBC and NTM groups due to its disease manifestation
and genotypic distinctiveness, having a significant reduction of its genome size and functional
genes.3, 9 As the causative agent of leprosy, M. leprae can infect the peripheral nervous system,
skin, and mucous membranes.3 Disease is associated with lesions, nodules, plaques, and skin
thickening.3 Being unable to propagate by standard in vitro methods, M. leprae is also extremely
fastidious. Instead, it must be grown in mouse footpads or armadillos. Leprosy remains an active
disease, with ~175,000 new cases reported in 2015 in India, Brazil, and Indonesia mostly.3 The
disease has left over 1 million people disabled worldwide, but the infection itself is highly
treatable.3
The Mycobacterium Tuberculosis Complex
Pulmonary tuberculosis (TB) is caused by a group of bacteria classified as the MTBC.
Well known members of the MTBC include Mtb, Mycobacterium bovis, Mycobacterium
africanum, Mycobacterium caprae, Mycobacterium microti, Mycobacterium canettii,
Mycobacterium pinnipedii, Mycobacterium mungi, and Mycobacterium orygis.2, 3 All of these
species are slow growing, genetically similar mycobacteria that infect various mammals,
including humans.3 The importance of their differentiation lies in their different host range,
epidemiologic patterns, and treatment outcomes.2
Members of the MTBC are highly similar, making differentiation by MALDI-TOF,
HPLC, and 16S rRNA gene sequences troublesome.3 Precise identification of clinical isolates is
difficult as a consequence. Alternatively, the GenoType MTBC probe assay by Hain LifeScience
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is effective for identifying a handful of the complex members.3 Despite this similarity, MTBC
organisms are highly dissimilar in their mammalian host range, morphologies, antimicrobial
susceptibilities, and geographic distributions.3

TUBERCULOSIS
TB is typically spread by airborne particles produced when a person presenting the
pulmonary disease coughs. After a patient inhales an aerosolized droplet from an infected person
or animal, infection can occur when the tubercle bacilli reach the lungs’ alveoli.2, 3 Initial
outcomes range greatly upon entry to the lungs. Host macrophages may successfully kill the
invading bacteria, the bacteria can become dormant causing a latent infection, or an active
disease may begin in the lungs, lymph nodes, kidneys, brain, larynx, and/or bone.3 In general,
those with active TB experience weight loss, loss of appetite, night sweats, fever, and fatigue. In
addition, pulmonary disease is associated with 3+ weeks of coughing sputum, coughing blood,
loss of breath, and chest pain.10
When the Mtb bacillus reaches the phagosome of an alveolar macrophage it can
effectively thwart acidification, but the host in turn responds by forming granulomas around the
infected cell.11 The granulomas are made up of layers of immune cells containing and attempting
to sterilize the infected macrophage, and it is within these structures that latent Mtb are often
maintained, sometimes for a lifetime, in a quiescent state of metabolic activity without active
growth.11 Upon suppression of the immune system, latent Mtb can be released from granulomas
to cause active pulmonary TB disease.11 Chronic latent infection is asymptomatic, but remains a
significant medical concern due to the continuous maintenance of a large tuberculosis reservoir
in the global population.3 These infected individuals are healthy and incapable of spreading the
infection through droplets, but will often test positive for Mtb presence.2 In addition, all of these
7

patients have the potential for development of an active tuberculosis disease, particularly when
carriers become immunosuppressed.2, 3 There is a 10% risk for latent individuals to develop
active tuberculosis in their lifetime.2
Tuberculosis Prevalence
TB mortality rate is the most prominent of all bacterial diseases, and comes in second as
the most prominent infectious killer only to HIV.2 The World Health Organization (WHO)
estimates that nearly a quarter of the world’s population currently has latent TB.12 These
individuals have a 10% risk of developing active TB disease sometime in their lifetime.2 There
were approximately 10 million new cases and more than 1.6 million deaths occurring from TB
infection in 2017 alone (Figure 1-3).12 Of the deaths, 1.3 million were HIV-negative individuals.
TB infects all age ranges, but rates among adults are higher. Although TB is not eradicated in
any country, 87% of cases occur in the WHO’s list of 30 high TB burden countries, with 66%
having occurred in India, China, Indonesia, The Philippines, Pakistan, Nigeria, Bangladesh, and
South Africa. In general, TB is rare in high-income countries, with only 6% of cases coming
from the Americas and the western European region.12

Figure 1-3. Graphic demonstration of worldwide tuberculosis prevalence in 2017.
Image demonstrates tuberculosis prevalence in 2017 as per the WHO’s 2018 “Global
Tuberculosis Report.” Adapted from [12].
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Additionally, those coinfected with TB and HIV are at a considerably increased risk for
complications and death, with nearly 9% of new cases in 2017 being of this type. This is of
particular concern in Africa where 72% of these co-infections took place.12 In order to
successfully eliminate TB disease, substantially more attention and resources must be applied to
the problem including political commitment, staff training, better laboratory services, and proper
patient management.
The WHO’s End TB Strategy
The WHO began its “End TB” strategy in 2015, with an ultimate goal of reducing global
incidence 10-fold by 2035.13 The plan uses a three-pillared approach, including advocating for
improved TB care and prevention, supporting bold government implemented policies to curb
disease, and supporting research in diagnostics, treatments, and vaccinations.13 The first
milestone is in 2020 and aims to see incidence rates fall 4-5% per year and mortality rate fall to
10%. By 2025, the goal is to see incidence fall by 10% per year and have mortality down to
6.5%. Currently, impressive reductions are occurring globally, but unfortunately are not strong
enough to reach the first milestone’s goals. As of 2017, the incidence rate is dropping at an
average rate of 2%, and the mortality rate is down to 16%. This is still a decrease from the 23%
mortality rate seen in 2000.12 Particular regions of the world have reached the 4-5% decrease in
incidence rate, but efforts must be increased in other regions.12
Tuberculosis Treatment and Prevention
Treatment has come a long way since 1800 when those diagnosed with “consumption”
were simply told to rest and eat nutritiously.14 Great strides began with the identification of Mtb
as the causative agent by Robert Koch in 1882, development of the BCG vaccine, and discovery
of effective antimycobacterial drugs. 14 As a result, there has been a steady drop in TB mortality
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rates throughout the mid-1900s. Unfortunately, in the late 20th century, reduced research in drug
and vaccine development in combination with the outbreak of HIV/AIDS has caused a rise in
disease incidence, allowing TB to maintain its status as one of the most deadly infectious
diseases in history.14
Currently, TB treatment is a long process requiring an intensive 2-month drug cocktail
phase followed by up to 18 more months on a less intensive regimen. Most of these multi-drug
cocktails are composed of a combination of isoniazid, rifampicin, pyrazinamide, and either
ethambutol or streptomycin. In the US, the precise drug combinations and regimens are
determined by publicly available CDC recommendations that take into account a patient’s health
status and the particular drug susceptibilities of the Mtb isolate as determined by in vitro
testing.14 Currently, the most preferred drug regimen is an initial 8-week phase of isoniazid,
rifampicin, pyrazinamide, and ethambutol followed by at least 18 weeks of isoniazid and
rifampicin that should be taken between 5-7 days per week.15 HIV positive individuals on
antiretroviral medication are recommended to be treated similarly, though interaction with a
patient’s antiretroviral therapy must be considered during treatment design to avoid certain drug
interactions.15
Treatment for those with a latent TB infection in the US is outlined by the CDC and is
influenced heavily by a patient’s risk factors and outcomes of their test results.15 The regimen
most recommended is a once weekly dose of isoniazid and rifapentine for 3 months.15
Additionally, it must be confirmed that a patient does not have an active disease before starting
them on the less intensive latent TB drug regimen. If a patient is identified as one that should
receive treatment, there are several regimen options that can be pursued.15
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Vaccination is a powerful tool for prevention of infectious disease, and its role in
prevention of TB has been pursued for over a century.14 The live attenuated nonpathogenic M.
bovis Bacillus Calmette-Guerin (BCG) vaccine was discovered in 1908, though its efficacy is
highly variable, and as a result is only considered useful in areas with highly endemic TB
burdens.14 There has been a race for the last two decades to develop a more efficient vaccine, but
the best efforts have so far been unsuccessful in clinical trials.14
Currently, the best strategy for prevention of TB disease is treatment of latent TB
infection and vaccination with the BCG strain. Latent TB is diagnosed when a patient receives a
positive tuberculin skin test (TST) but is displaying no symptoms and has no acid-fast bacilli
appearing in their sputum.15 For those individuals that had previously received the BCG vaccine,
false positive skin tests do occur and interferon-gamma release assay (IGRA) blood tests should
be used to diagnose infection instead.15
For those with latent TB, treatment is highly recommended, especially for HIV positive
individuals and children. Nearly 1 million HIV positive patients with latent TB had been started
on treatment in 2017, with coverage of eligible patients ranging from 1 – 50%, depending on the
region. Similarly, 23% of eligible children with latent infections were started on treatment. The
BCG vaccine is recommended for all children in countries with high TB prevalence, and 158
countries offer the vaccine nationally.12
Drug Resistant Tuberculosis
The complexity of TB treatment regimens stems greatly from Mtb’s intrinsic and
adaptive antibiotic resistances, of which the latter often occurs in response to treatment
inadequacies.14 Multi-drug resistant TB (MDR-TB) are isolates that are resistant to the two most
potent first-line anti-TB drugs, rifampicin and isoniazid.16 Extensively-drug resistant TB (XDR-
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TB) are a more rare but extremely dangerous strain that are also resistant to a fluoroquinolone
such as ciprofloxacin and one or more of the second-line drugs, such as amikacin.16 The CDC
states that the costs in 2016 for treatment of TB ranged from $18,000 for drug-susceptible cases
to $513,000 for XDR-TB cases, highlighting the burden of resistance on effective care.16
It is believed that 5% of new cases in 2017 were rifampicin resistant strains (RR-TB), and
82% of these could be further classified as MDR-TB.12 The rate of XDR-TB was as high as 8.5%
of the MDR-TB cases in 2017.12 Neary half of these drug resistant TB cases occurred within
India, China, and Russia. Persistent cases of TB that were treated prior to 2017 showed a higher
proportion of drug resistance than new cases, at an average rate of 18%, though cases in the
region of the former Soviet Union reached above 50%.12
Tuberculosis: Moving Forward
The WHO has set vital but ambitious goals to reduce TB disease substantially, which
cannot happen without breakthroughs in research and development over the next decade. The
scientific community must work hard to develop effective vaccines to decrease the rate of new
infections, rapid and affordable diagnostics, and new drugs for targeting latent TB and drug
resistant strains. As of 2018, 20 drug and 12 vaccine candidates were in clinical trials. The feat of
the End TB initiative has proven difficult, especially in a climate of low science funding.13
Current funding levels are less than half of what the WHO estimates is needed to reach their
ambitious goals.13 To curve the trend of this historical killer, significant breakthroughs must be
made to improve the arsenal of TB prevention and treatment tools.
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SIDEROPHORE MEDIATED IRON ACQUISITION IN MYCOBACTERIA
Nutritional Immunity
The term nutritional immunity was coined in 1975 by Eugene Weinberg to describe the
methods plants and animals use to sequester iron from microbial invaders.17 Nutritional
immunity has since been extended more broadly to the limitation of all transition metals by the
host and includes the way a host re-directs their toxic properties against pathogens.18 Transition
metals in general are of high importance due to their unique ability to exhibit multiple valences,
permitted by an incomplete inner subshell where electrons can be lost.18 This quality allows for
their use in redox reactions as well as catalytic functions in conjunction with proteins called
metalloenzymes. Transition metals are vital for normal functioning of DNA replication, cellular
respiration, energy generation, and many other functions.19-21 Metals such as copper and zinc join
iron as important transition metals in living organisms, but iron is the most commonly used in
redox reactions.18
The unique qualities that make transition metals powerful tools in biological systems can
also make them highly toxic. Often, free transition metals can lead to disruption of metabolic
processes, oxidative stress, and incorrect incorporation of specific metals in metalloenzymes.22
Due to the concurrent high importance and reactive nature of these elements, organisms have
developed complex means of storage and quantity control. Interestingly, the mechanisms used to
restrict the levels of toxic transmission metals double as important tools in nutritional immunity.
During infection, bacterial invaders also need micronutrients such as iron to survive. Within the
mammalian host, bioavailable iron is exceptionally finite.20 Upon infection, the host immediately
restrict the amount of circulating iron to withhold the nutrient.20 This restriction of access to iron
and other transition metals and the redirecting of their toxic activity against invaders has led to a
complex arms race, resulting in the arise of bacterial systems for iron thievery.
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The Host’s Restriction of Iron
As the most abundant transition metal in humans, stringent regulation of iron by
adsorption, transport, and storage is vital. Most iron in mammals is recycled and found in red
blood cells, with a small amount being replenished by ingestion.18 In red blood cells iron is
complexed with the hemoglobin cofactor molecule heme. Heme’s iron-sulfur clusters are
responsible for oxygen transport and cellular respiration.18, 22 When hemoglobin is released by
red blood cells it is rapidly bound by haptoglobin and haemopexin, further reducing likelihood of
bacterial acquisition.18 Most freely circulating iron is found bound to the iron binding protein
transferrin, leaving very little free soluble iron available for bacterial invaders. In aerobic
conditions at physiological pH, iron is oxidized from the ferrous to ferric form (Fe2+ to Fe3+),
which can be bound by the circulating transferrin.18, 21, 22 Transferrin effectively delivers iron to
host cells for their own cytoplasmic storage in the iron binding ferritin protein, which further
limits iron from use by extracellular pathogens.18, 22 Ultimately, the homeostatic control of iron
in mammals is sufficient to limit free iron to levels far below what is needed for bacterial growth
sufficient for infection.22
Despite this, several host pathways for further limitation of iron have arisen to counteract
successful bacterial infection. Two of the methods induced by the host upon infection include
hepcidin upregulation and generation of ferric-iron binding proteins. The major iron regulating
hormone of mammals is hepcidin, which is induced upon infection and is known to stimulate the
internalization and degradation of the sole non-heme iron exporter, ferroportin.22 This further
reduction of free extracellular iron is thought to cause a stringent anemia during inflammation
that inhibits growth of invading bacteria.22 In addition to the hepcidin upregulation, phagocytic
cells localize the natural resistance associated macrophage protein I (NrampI) to the phagosome
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to pump both iron and manganese out of the phagosomal compartment and away from
intracellular pathogens, such as Mtb.18, 23
Ferric iron binding proteins are also utilized by the host to limit iron from invaders,
including basal levels of transferrin and the infection-induced lactoferrin.22 At the site of
infection, lactoferrin is upregulated and released by neutrophils. Lactoferrin has a higher affinity
for iron than transferrin, which allows it to reduce iron below basal levels. Iron-loaded lactoferrin
is subsequently taken up indiscriminately by surrounding cells to deliver iron to ferritin for
storage.22 Lactoferrin and transferrin also have secondary roles when taken up by any infected
cells at the site of infection to generate reactive oxidative species that are toxic to invaders.22
The human host factor Lcn2, also referred to as siderocalin, is a defense mechanism
against bacterial iron scavenging by small chelating molecules called siderophores.18, 22
Structural classes of siderophores play a large role in a bacteria’s iron scavenging capabilities
due to recognition by siderocalin, which effectively binds and subdues the chelators before they
can deliver iron back to the bacterial cell.22
Siderophores: Bacterial Iron Acquisition
In response to a host’s limitation of iron, bacterial pathogens have mechanisms of
circumvention necessary for a successful infection. Of particular importance across many
bacterial species is the use of iron chelating siderophores molecules.18, 22 Siderophores are low
molecular weight metabolites secreted by bacteria with potent affinities for ferric iron. To bind
the iron, most siderophores utilize deprotonated oxygens throughout their structure to
encapsulate the positively charged metal ion.22 Iron-loaded siderophores are then recognized by
the bacterium and transported in. Iron is then released by enzymatic degradation of the chelator
or reduction of the bound ferric iron to its ferrous state.22
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Figure 1-4. Division of representative bacterial siderophores into the four most recognized
structural classes.
The iron binding moieties defining the different structural classes of the siderophores are colorcoded (catecholates in green; hydroxamates in blue; carboxylates in red; phenolates in yellow).
Adapted from [24].
There are five structural classes of iron chelating siderophores defined by their iron
binding moieties including catecholates, hydroxamates, carboxylates, phenolates, and mixed
(Figure 1-4). In some instances, phenolates are considered a part of the mixed siderophore class
due to their other unique iron binding groups (not shown). Since the discovery of three
siderophores around 1950, over 500 different siderophore structures have been described today,
falling mostly into the catecholate, hydroxamate, and mixed siderophore classes.22
The Mycobacterial Siderophore Systems
Iron is required by pathogenic mycobacteria for the activity of many enzymes and is
vitally important for the generation of energy in redox reactions.19-21 TB exacerbation has been
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linked to dietary iron supplementation in mice and early treatment attempts with iron salts was
seen to worsen disease.25 Interestingly, individuals with mutations in the NrampI transporter
responsible for removing iron from the phagosomal compartment have increased susceptibility
where Mtb resides.25 It is evident that iron is essential for successful Mtb infection.

Figure 1-5. Flow chart of the three major siderophore classes produced by Mycobacterium
species.
Virtually all Mycobacterium produce one or both of the mycobactins, while only two known
non-pathogenic species produce an additional siderophore called exochelin. Adapted from [26].
Mycobactins (MBTS) are low molecular weight mixed-type siderophores (phenolate and
hydroxamate binding moieties) which bind ferric iron with a remarkably high affinity, and are
used by virtually all mycobacteria to chelate iron from their surroundings for growth in low-iron
conditions.27 The MBTS include the cell-associated lipid-soluble mycobactin (MBT) and a
carboxylated water-soluble derivative called carboxymycobactin (cMBT) (Figure 1-5). They can
be isolated from all species except M. leprae, M. microti, Mycobacterium paratuberculosis, and
Mycobacterium vaccae.9, 27 M. smegmatis and Myocobacterium neoaurum are the only two
mycobacterial species known, thus far, to also produce a hydroxamate penta-peptide siderophore
known as exochelin (EXO) (Figure 1-5).22, 26
The MBTS of Mtb are required for virulence in macrophage, mouse, and guinea pig
models of infection, and M. bovis requires MBTS for persistence in its native bovine host.23, 28-30
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Additionally, a study of Mtb infected mice demonstrated that treatment with a mycobactin
biosynthesis inhibitor significantly reduces the bacterial burden in the lung.31 Mtb was shown to
have decreased growth in human serum in the presence of transferrin, but growth was restored
with the addition of MBT, demonstrating the importance of the system for iron capture from the
host.32 MBTS’ iron affinity is strong enough to steal directly from human iron binding factors
such as transferrin and ferritin, lending to their importance for virulence.25
Structure of the Mycobactin Siderophores
MBTS have a unique structure composed of a 2-hydroxyphenyloxazoline ring on one end
derived from salicylate and serine precursors, linked to a N-hydroxylysine, β-hydroxy acid, and
finished with a cyclic N-hydroxylysine (Figure 1-6). Though this core is fairly conserved among
the genus, there are 5 R-groups at which modifications have been observed among different
species, including position 6 of the salicylate moiety, the 5’ position of the oxazoline ring, the
two alkyl groups of the β-hydroxy acid, and the end of the central N-hydroxylysine (Figure 1-6).
A characteristic long alkyl side chain is typically found on the central N-hydroxylysine, except in
the case of M. marinum and some siderophores of the closely related Nocardia genus, for which
it is located on R3 (Figure 1-6).27, 33, 34 The MBT and cMBT of a single organism are identical
except for the shorter alkyl side chain of cMBT terminating with a carboxyl group.33 It is this
carboxylation of the shorter side chain that makes it more water-soluble than their lipophilic
MBT partners, allowing them to be secreted into the environment for iron capture.33 The MBTS
are typically made from 5 standard precursors. These include salicylate and serine for the 2hydroxyphenyloxazoline ring, propionate for the β-hydroxy acid moiety, and two L-lysines to
form the two N-hydroxylysine groups (Figure 1-6).27
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Figure 1-6. Structure of the mycobactin siderophores.
The structure of the general mycobactin backbone is depicted, and the five R groups where
variations between species are colored in red. The different aliphatic R5 groups of the lipophilic
mycobactin (MBT) and hydrophilic carboxymycobactin (cMBT) variants are depicted on the top
right. Dotted lines represent where the five precursors are incorporated during siderophore
biosynthesis. Adapted from [27].

Genetic Loci Involved in Biosynthesis of the Mycobactins
The genes for proteins used for the production of MBTS are organized in the conserved
genetic loci mbt-1 and mbt-2. The 25-kb mbt-1 locus is responsible for the synthesis of the core
structure and includes genes for 10 enzymes from mbtA – mbtJ (Figure 1-7).34, 35 The second 3.5kb mbt-2 locus is responsible for the synthesis and incorporation of the alkyl side chain on the
central N-hydroxylysine and includes genes for 4 enzymes from mbtK – mbtN (Figure 1-7).36
The initial salicylate precursor is known to be synthesized by MbtI37 and the mechanism for
carboxylation of the alkyl side chain of cMBT has yet to be described.
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Figure 1-7. Organization of the M. tuberculosis mycobactin biosynthesis gene clusters.
The mbt-1 and mbt-2 gene clusters of M. tuberculosis responsible for biosynthesis of mycobactin
siderophores are depicted. Grey boxes represent regulatory IdeR boxes, which are bound by IdeR
to repress expression in high-iron conditions.38 The irtA and irtB genes are included due to their
proposed role in uptake of iron-loaded mycobactins. Adapted from [39]
Model for Biosynthesis of the Mycobactins
A model for MBTS biosynthesis has existed for 20 years, but biochemical analysis of the
components’ roles is only partially confirmed. The initial salicylate starter unit is produced by
the salicylate synthase MbtI in a two-step conversation of chorismate. Initially, MbtI binds
chorismate and rearranges the pyruvate orientation in a Mg2+ dependent manner to produce
isochorismate, followed by removal of the pyruvate to create salicylate. In the absence of Mg2+,
MbtI will rearrange the pyruvate onto the carboxylate of the aromatic ring to generate
prephenate, demonstrating a chorismite mutase activity seen in many other Mtb enzymes.37
The MbtA to -F enzymes of mbt-1 are considered to form a hybrid complex with
nonribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) function, while
members of the mbt-2 locus display PKS activity.36, 40 For NRPSs, after activation by
adenylation, aryl acids or amino acids are captured on two neighboring carrier domains and
condensed to link directionally by a covalent bond. In its most simplified model, three domains
(adenylation, carrier, condensation) form an NRPS module, and the number of modules in a
complex corresponds to the number of precursors incorporated into the final product.40 PKSs are
similar in their arrangement of repeating domains, but synthesis begins with the recognition of
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thioesterified carboxylic acids by an acyltransferase domain which then tethers the activated
substrate to a carrier domain.41
MbtA has been described as the adenylation enzyme necessary for the initial step in
production of MBTS by activating salicylate to its adenylated form.35 Subsequently, MbtA
transfers the salicyl moiety covalently from the adenylate to the sulfhydryl of the
phosphopantetheinyl group of the NRPS-complex component MbtB.35 The addition of this
phosphopantetheinyl group is accomplished by the phosphopantetheinyl transferase PptT,
encoded outside of the Mtb mbt-1 locus.35 MbtB then catalyzes the cyclization of either a serine
or threonine residue to form the 2-hydroxyphenyloxazoline ring of the MBTS structure.35, 40
It has been shown that the NRPS enzymes MbtE and MbtF incorporate the Nhydroxylysines of the MBTS backbone.40 The hydroxylation of the central lysine to Nhydroxylysine is accomplished by MbtG before incorporation in the scaffold, based on a ∆mbtG
mutant’s 98% reduction in total MBTS which lacked hydroxylation.36, 40 MbtC and MbtD
together have the complete module necessary for a PKS complex, and are thought to be
responsible for the production and incorporation of β-hydroxybutyrate by recognition and
condensation of malonyl-CoA and acetyl CoA.27 MbtH has been shown to stabilize and increase
function of NRPS components such as MbtB, MbtE, and MbtF.40
The mbt-2 locus was identified more recently, but was validated in vitro to be responsible
for the transfer of the fatty acyl group to the central N-hydroxylysine of the MBTS scaffold.36
MbtM is a fatty acyl-AMP ligase capable of adenylating a range of medium to long chain fatty
acids, and was also shown to deliver an activated lauric acid to the carrier protein domain of
MbtL. MbtN was then described to introduce a double bond on the attached lauroyl chain.36
MbtK has been established as a regulator of MbtM function by post-translational acetylation.36, 42
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Interestingly, MbtG of the mbt-1 cluster has been implicated in the transfer of this fatty acyl
chain the central lysine of the MBTS backbone.36, 40
Trafficking of the Mycobactins
The mechanisms of trafficking (secretion and uptake) MBTS during iron capture are still
under investigation.21, 25 It is proposed that MmpL and MmpS transporter complexes export the
siderophores across the inner membrane, then MBT remains cell associated while cMBT is
secreted (Figure 1-8).21 Mutants lacking MmpS4 and MmpS5 are unable to secrete the
siderophores and have substantial defects, demonstrating pronounced low-iron growth defects
and attenuation in mice.43 These pronounced phenotypes are convoluted because cytoplasmic
accumulation of MBTS is likely toxic to the bacteria.25, 43 The precise mechanism of subsequent
transport across the outer mycobacterial cell envelope remains undescribed.

Figure 1-8. Representation of mycobactin trafficking in M. tuberculosis.
A proposed model of mycobactin (MBT) and carboxymycobactin (cMBT) trafficking is
proposed here, though the precise mechanism of the various proteins involved are not certain.
Mechanisms of transport through the outer membrane (OM), mediation by ESX-3 system
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factors, and the role of mycobacterial vesicles are not included due to uncertainties about their
roles. Adapted from [43].
It is thought that cMBT sequesters exogenous iron for delivery back to the cell.
Tentatively, cBMT may deliver iron to MBT, which is then imported through the IrtAB
complex, which also reduces Fe3+ to Fe2+ for storage by BfrA and BfrB.21 Alternatively, cMBT
itself may be delivered to the cytosol by IrtAB, making interaction between the two siderophore
variants unnecessary. The latter is supported by the rescue of a Mtb mbtB mutant’s growth with
the supplementation of iron loaded cMBT in low iron medium, demonstrating uptake
independent of MBT production.44 Interestingly, Mtb mutants with disruptions in IrtAB function
only have a growth reduction in low iron conditions, unlike MBTS biosynthesis mutants that con
not grow without iron added.44 This suggests secondary modes of import likely exist. Deletions
in the IrtAB complex did lead to reduced growth in mouse lungs, indicating it’s importance in
vivo.44 Release of iron by a reductive process rather than enzymatic degradation allows for
siderophore recycling and a lower metabolic cost.
Interaction of the Mycobactins and Other Cellular Systems
While recent experimental data suggest that the Type Seven Secretion System ESX-3 has
a role in uptake of MBTS, its precise function is not yet clear.21 Secreted Esx, PE, and PPE
proteins potentially interact with the siderophores themselves to aid recapture, as recently
proposed.23, 45 Mutational analysis previously described the M. smegmatis ESX-3 locus as
essential for mycobactin uptake.46, 47 Interestingly, compared to a MBTS deficient Mtb ΔmbtB
strain, mutants with defective ESX-3 require 10-fold more MBT to restore growth on agar
medium.23 In Mtb, ESX-3 has a secondary role for virulence that is unrelated to mycobactin
mediation, possibly due to other secreted protein substrates.23 The mechanism of ESX protein
transport across the outer mycobacterial cell envelope remains to be described. Many secreted
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protein substrates of these systems are commonly encoded outside of the ESX genetic loci.45, 48,
49

A link between MBT, mycobacterial extracellular lipid vesicles, and iron acquisition has
been recognized recently. It has been found that extracellular membrane vesicles are loaded with
MBT, but only when the bacteria are grown in low iron conditions.50 These vesicles are involved
in iron acquisition, as shown by the rescued growth of a MBTS deficient Mtb strain in low iron
conditions after the introduction of vesicles from the WT strain.50 Proteomic studies of
mycobacterial vesicles have identified several components of T7SSs in these vesicles, including
the MycP3 protease of the ESX-3 system.50, 51 It is possible that this vesicle transport of
mycobactin may help with sharing of iron loaded MBTS between Mtb cells, or to help deliver
MBTS to a host’s iron located in hydrophobic environments.25
Implications of Mycobactins System Disruptions on Growth and Infection
There is conflicting evidence as to whether the MBTS are required for growth in high
iron medium in vitro. It has been established that strains deficient in mycobactin production or
trafficking have a substantial growth defect when grown in low iron growth medium.23, 28, 52, 53, 54
In high iron conditions, the growth capabilities of these mutants are conflicting between different
reports. Growth defects have been recognized in Mtb in high iron medium for strains with
mutations in ∆mbtB23, ∆mbtD52, 53, ∆mmpS4/S553, and ∆mbtG54. In contrast, different strains with
mutations in ∆mbtB28 and ∆mbtK54 have shown no defect in high iron conditions. Interestingly,
M. smegmatis strains that are deficient in biosynthesis of both EXO and MBTS only have growth
defects in low iron medium, as shown in this thesis work and by others.47, 53 The disparity
between growth phenotypes between the two Mtb ∆mbtB mutants indicates an experiment
specific phenomenon not currently understood. The implications of a growth defect in high iron
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conditions make targeting of the mycobactin biosynthesis and trafficking pathways more
desirable. In view of the discrepancies related to high iron growth, the naturally iron-restrictive
environment of the macrophage’s phagosomal compartment points to biosynthesis of MBTS as a
good drup target, nonetheless.
Elimination of MBTS has been associated with dramatic attenuation, helping to validate
the biosynthetic pathway as an attractive target for antimicrobial inhibition.23, 27, 29 It was
reported by Reddy et al. that a Mtb ∆mbtE mutant is clearly attenuated in the guinea pig model.29
Despite this, results since have appeared to be mouse-strain dependent, and perhaps linked to the
nrampI genotype of the mouse strain. The BALB/c and C57/B6 mouse strains carry the
dysfunctional nrampS gene, leaving them with no mechanism to deplete phagosomal iron levels,
and in theory reducing the need for Mtb to need MBTS for successful infection. Interestingly,
Jacobs and coworkers found that a ∆mbtB Mtb mutant is only mildly attenuated in nrampIS
BALB/c mice, but was highly attenuated in CBA mice which carry the functional nrampIR
gene.23 With the defective nrampIS C57/B6 strain, a ∆mbtk Mtb mutant was only described as
having “early virulence attenuation” due to a delay before infection caught up with positive
controls.55 Interestingly, studies with Mtb mutants dysfunctional in MBTS export and import
have less of a dependency on the nrampI genotype of the mouse strain. Mutants with a
dysfunctional MmpS/L MBTS export system have substantial attenuation in C57/B6 mice43 and
deletions compromising the IrtAB import system resulted in attenuation in BALB/C mice.44 It
remains unclear why mutants in MBTS biosynthesis versus those in trafficking do not agree.
Biosynthesis of Mycobactins as a Drug Target
During infection, the host only has a limited supply of iron that is protected with various
binding mechanisms in effort of warding off invaders. The ability of a bacteria to acquire iron
25

from the host can determine its success as a pathogen. Interestingly, the guinea pig and some
mouse models of infection associate dysfunctional MBTS systems with dramatic attenuation and
decreased survival rates, though there remains some controversy in view of results from mouse
model studies.23, 52, 53, 28, 29, 53, 54 At a minimum, this collection of evidence at least warrants the
investigation of this pathway as a drug target, which could ultimately be used as either a standalone or adjuvant therapy for those with TB if proven effective. There have been several
promising examples of inhibitors targeting this system in the last two decades.
Analogues with structural similarity to the mycobactin scaffold have been pursued as
potential inhibitors of the various players involved in synthesis and trafficking, relying on the
potential binding of similar moieties to compete with natural substrates. Of particular interest
were the Diaryl-pyrazoline (DAP) derivatives mimicking MBTS’ 2-hydroxyphenyloxazoline
ring and (2E)-2-benzylidene-N-hydroxyhydrazine carbo(ox/thio/oximid)-amide (BHHC)
derivates mimicking the hydroxyphenyl cap, demonstrated by the Quadri lab.56, 57 Of the 32
analogues pursued, 17 displayed antimicrobial activity against Mtb. Two were dependent on a
low-iron environment for activity, consistent with the ideas the MBTS are required for iron
capture.56, 57 As noted, it is possible that iron-binding capabilities of these inhibitors may further
limit iron availability, in the medium or intracellularly, thus negatively effecting viability in the
assay. If the derivatives could gain access to the cell, perhaps via the MBTS trafficking systems,
they may also inhibit essential functions due to cytoplasmic iron chelation.56 Similarly, the
transvalencin siderophore metabolite produced by Nocardia transvalensis, with close structural
similarity to MBT, displayed an antimycobacterial activity in iron rich conditions, potentially
inhibiting in similar ways to the DAP and BHHC derivatives.58
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Inhibition of the salicylate synthetase MbtI has also been explored.59 MbtI has no human
orthologues and has been deemed essential based on Mtb whole-genome transposon mutagenesis
libraries and the challenging manipulation of the gene in M. smegmatis.60, 61 Aldrich and
coworkers screened 35 inhibitors with known activity against chorismate synthase family
proteins and found five benzimidazole-2-thione derivates with low-micromolar IC50 values
against MbtI.59 Manos-Turvey and coworkers explored 2,3-dihydroxybenzoate analogues
mimicking the structure of isochorismate as MbtI inhibitors and found several compounds with
low-micromolar biochemical activity and promising antimicrobial activity against Mtb.62 It has
been proposed that antimicrobial activity of chorismate and isochorismate mimicking inhibitors
may be due to disruption of many biosynthetic pathways utilizing chorismate as a substrate,
perhaps explaining the activity in high-iron conditions and pointing to a mode of action more
broad than MBTS pathway disruption.62 A recent study identified compounds by a virtual
screening method utilizing the structure of MbtI with strong biochemical and antimycobacterial
activity.63 Interestingly, the derivative with the best antimicrobial activity was shown to be iron
concentration dependent and successfully diminished production of MBTS, suggesting the mode
of action is related to the MBTS system.63
An important step towards the use of MBTS biosynthesis as a drug target was the
characterization of the first-in-class nucleoside antibiotic salicyl-AMS (5′-O-[Nsalicylsulfamoyl]-adenosine) as an inhibitor of the salicylate adenylation enzyme MbtA by the
Quadri and Tan labs.64 Salicyl-AMS mimics the salicyl-adenylate intermediate structure, but has
a replacement of the acylphosphate linker with an acylsulfamate (Figure 1-9A).65 This
acylsulfamate stabilizes the compound and prevents downstream delivery to the MbtB carrier
protein domain’s phosphopantetheinyl group (Figure 1-9B).65 Salicyl-AMS has been proven to
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inhibit MbtA adenylation of salicylate, diminish production of MBTS in Mtb (Figure 1-9C), and
display antimicrobial activity against Mtb in an iron concentration-dependent fashion.64 These
findings were subsequently confirmed independently by other groups.66 As a result, extensive
structure-activity relationship (SAR) analysis of salicyl-AMS has been pursued.65-73

Figure 1-9. Salicyl-AMS inhibition of MbtA during mycobactin biosynthesis
(A) Nucleoside antibiotic salicyl-AMS and the salicyl-AMP intermediate synthesized by the
salicylate adenylation enzyme MbtA. (B) Reaction catalyzed by MbtA during biosynthesis of MBTS.
MbtA catalyzes formation of the first covalent acyl-enzyme intermediate during MBTS acyl-chain
assembly through a mechanism involving two-half reactions. The first half reaction is the ATP-dependent
adenylation of salicylic acid to generate a salicyl-AMP intermediate that remains non-covalently bound to
the active site. The second half-reaction is the transfer of the salicyl moiety of the adenylate onto the
phosphopantetheinyl group of the carrier protein domain of the peptide synthetase MbtB. (C)
Representative mycobactin siderophores of M. tuberculosis. R represents variable fatty acyl groups
(mycobactin variants) or acyl substituents terminating in a carboxylate or a methyl ester
(carboxymycobactin variants). All of these variants are herein collectively referred to as MBTS. Adapted
from [74].
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The Quadri and Tan labs recently reported in vivo efficacy of salicyl-AMS in a mouse
model of TB.31 Importantly, this work showed that monotherapy with salicyl-AMS at 5.6 or
16.7 mg/kg correlated with a significant reduction of Mtb growth in the mouse lung and supports
MbtAtb as a promising target for the development of novel TB drugs. However, in vivo toxicity
at ≥16.7 mg/kg doses was observed, impeding further dose escalation to improve efficacy. Thus,
there is a continued need to develop new salicyl-AMS analogues with the long-term goal of
improving pharmacokinetics, efficacy, and toxicity profiles.
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RESEARCH OBJECTIVES
Much has been done to characterize the Mtb MBTS system in the 21st century, and its
potential as a target for novel antimicrobials has been noted. Inhibition of the MbtA salicylate
adenylation enzyme by salicyl-AMS has established this novel mode of action as promising in
the development of new antibiotics active against Mtb. Despite the biochemical, antimicrobial,
and SAR characterization of the inhibitor, further work must be done to evaluate the class for its
clinical worth. This dissertation seeks to comprehensively explore the kinetic and antibacterial
properties for salicyl-AMS, six of its strongest analogues, and 2 novel analogues to add to the
SAR analysis. The research reported in this dissertation explores:
I.

Development of an optimal strategy necessary for purification of the MbtA protein target
in quantity and purity sufficient for thorough inhibition analysis, Optimization of HAMesG assay conditions for MbtA activity, and characterization of kinetic parameters of
the recombinant MbtA in this assay to validate its use to assess MbtA inhibitors.

II.

The study of MbtA inhibition by salicyl-AMS and the eight analogues of interest to
further probe the SAR of the group. The study investigates intrinsic inhibition of MbtA
by salicyl-AMS, determination of kinetic parameters useful for evaluating clinical
potential, and analysis of the analogues’ mechanism of inhibition.

III.

An assessment of the antimycobacterial activity and postantibiotic effect of salicyl-AMS
and the eight analogues of interest using a strain of non-pathogenic, fast-growing M.
smegmatis engineered for susceptibility dependent on the heterologous expression of
MbtA from Mtb.
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CHAPTER 2: CLONING, OVEREXPRESSION, PURIFICATION, AND
KINETIC EVALUATION OF RECOMBINANT MbtAtb
Introduction
MbtA is an essential enzyme for the biosynthesis of mycobactin siderophores (MBTS).
MBTS are high-affinity iron chelators involved in ferric iron scavenging and uptake.34, 35 MbtA
has been described as the adenylation enzyme necessary for activation of the salicylate starter
unit into its acyl adenylate. Subsequently, MbtA attaches the salicyl-AMP molecule covalently to
the phosphopantetheinyl group of the MbtB NRPS-complex component. With no human
homologues, MbtA has been proposed as a prime candidate for targeting by rationally designed
potential antimicrobials.35 For the last 15 years, a new class of nucleoside antibiotics targeting
MbtA have been pursued following discovery of the first-in-class antibiotic salicyl-AMS.64
The MbtA of Mtb (MbtAtb) was first purified in pursuit of describing the mbt-1
mycobactin synthesis locus.35 Initially, MbtAtb tagged with a hexahistidine tag alone would not
express.35 Instead, a C-terminal hexahistidine tag and a N-terminal maltose binding protein tag
were used, and the latter was cleaved from the final product.35 Inclusion of the maltose binging
protein modestly improved expression and allowed for a scarce 0.1 mg/L final yield of pure
protein.35 In 2005, Ferreras and coworkers pursued purification of MbtAtb again, instead using a
cleavable tandem N-terminal hexahistidine and SUMO tag system to improve protein expression
and solubility. Although an increase in the final yield compared to the prior method was
mentioned, the value itself was not reported.64 To build upon this progress, Aldrich and
coworkers attempted the same tagging strategy in an E. coli strain coexpressing the GroEL and
GroES chaperones from plasmid pGRO7 to further solubilize the recombinant MbtAtb and
reported a 20-fold increase in yield compared to the original method (2 mg/L).65 Despite these
advances in MbtAtb expression and purification, the best reported yield remains subpar.
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Unfortunately, a high-throughput comprehensive analysis of inhibitors is challenging without a
highly effective means of producing the target protein.
Due to poor expression of MbtAtb by the E. coli host and its poor solubility, MbtAtb has
been historically challenging to purify. Previous purification strategies have required multiple
columns to achieve sufficient purity, further reducing final protein yield. We have found that
binding of recombinant MbtAtb to the Ni-NTA resin is poor with a standard hexahistidine tag,
with much of MbtAtb ending up in the flow-through (not shown). If binding affinity of MbtAtb to
the column resin is increased, it may be possible to achieve suitably pure protein in larger
quantities without the need for extra purification steps. Additionally, a tag that does not require
cleavage and does not compromise enzyme activity can circumvent extra purification steps that
decrease yield and reduce enzymatic activity due to denaturation during extended manipulations.
Increasing histidine tag length from the traditional six residue length has been shown to
strengthen interaction with the Ni-NTA resin and alter the imidazole concentration needed for
elution of the protein of interest. For E. coli serine receptor (Tsr), increasing the tag by two and
four histidine residues correlated with increased imidazole concentrations for target elution and
an improvement of final purity due to contaminants eluting earlier.75 Similar results were seen
for a unique double-hexahistidine tag on GFP, in which the protein bound the Ni-NTA resin 6-8
fold stronger.76 This double-hexahistidine tag was used on the C-terminus alone and was
composed of two hexa-histidine tags separated by an 11 amino acid peptide spacer, and was
attached to the protein by a second linker optimized for protein stability.76, 77 Additionally, use
of a hexa-histidine tag on both termini had a similar effect on increasing binding strength.76
To this end, we opted to test the use of 10 differently histidine-tagged recombinant
MbtAtb variants. Tags were included on the N-terminus, C-terminus, or on both termini at the

32

same time. Small-scale purifications were used to determine the best candidate, and appropriate
kinetic assessment of the best MbtAtb candidate was done to ensure catalytic activity was not
negatively affected.
It has been noted that when proteins are expressed in a heterologous host they can lose
expression efficiency due to an organism’s codon bias, in which certain codons are infrequently
used.78 This bias can be reflected in rare or lacking tRNA populations in the host, for which
corresponding codons in genes heterologously expressed from other organisms can result in
translational stalling, premature translation termination, amino acid mis-incorporation, and
translational frameshifting.79 Codon optimization is often a means of improving this problem,
and several algorithms exist to help alleviate codon bias challenges.80 In view of these
considerations, we have pursued codon optimization and alternative tagging strategies of MbtAtb
in hopes of increasing yield and purity to suit the needs of studies aimed at evaluating potential
MbtAtb inhibitors.
With a newly modified enzyme, it is vital to ensure that catalytic integrity has been
maintained before progressing it towards inhibitor characterization. This can be done by
measuring the kinetics of an enzyme’s catalytic reaction, including Km and kcat. The reaction of
the enzyme (E) and substrate (S) complex (E-S) is in reversible thermodynamic equilibrium with
the two main rates defining it being the dissociation rate (koff) and association rate (kon).81 This
occurs by formation of a series of intermediate species, directing the S towards the product (P)
state.81
The kinetic “Michaelis constant” (Km) is most often used to measure E and S binding
affinity instead. The Michaelis constant approximates E-S binding affinity by measuring rate of
catalysis at different substrate concentrations.81, 82 This kinetic quantification of catalysis is far
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easier to measure than the dissociation constant (KD) of E and S binding, which is a
thermodynamic equilibrium parameter taking into account the many intermediate steps during
catalysis.81 The working definition of Km is the substrate concentration that yields half the
enzyme’s maximum velocity (V) of product formation (½Vmax).81, 82 The Km is approximately
equal to the concentration of substrate leading to half saturation of an enzyme’s active sites, but
it is also affected by the rate of product formation, making turnover rate (kcat) an important
parameter to keep in mind as well.81 A small Km indicates a high affinity between enzyme and
substrate.
The kcat is a composite rate constant representing the turnover of E + S to E + P by the
enzyme.81, 82 This encompasses multiple chemical steps but is dominated by the rate-limiting E +
S to E-S(transition) step, due to the large amount of free energy stabilizing it here when
reached.81 Of course, enzymatic rate enhancement itself relies largely on increasing the
likelihood of reaching this transition state.81 The kcat can be affected experimentally due to
solution conditions, substrate identity, enzyme mutations, and presence of an inhibitor.81, 82
We have set out to comprehensively characterize the kinetic parameters of the newly
tagged MbtAtb variant to ensure protein fidelity. We set out to then modify a generic continuous,
spectrophotometric adenylation enzyme assay (HA-MesG assay) to produce optimal MbtAtb
activity, allowing for a decrease in protein input in a format allowing for higher-throughput
analysis of MbtAtb inhibition than has been achieved before.

Materials and Methods
Bacterial culturing and recombinant DNA manipulations. Routine culturing of E. coli
strains was done under standard conditions in Luria-Bertani media.83 When required, kanamycin
(30 μg/ml), chloramphenicol (34 μg/ml), ampicillin (100 μg/ml), sucrose (2%), and/or 5-bromo34

4-chloro-3-indolyl-β-d-galactopyranoside (X-gal, 70 μg/ml) were added to the growth media.
DNA manipulations were carried out using established protocols and E. coli DH5α as the
primary cloning host.83 PCR-generated DNA fragments used in plasmid constructions were
sequenced to verify fidelity. The oligonucleotides used in this study are shown in Table S3.
Unless otherwise indicated, molecular biology, biochemical, and microbiology reagents were
purchased from Sigma-Aldrich Inc., Thermo Fisher Scientific Inc., New England Biolabs Inc.,
QIAGEN Inc., or Integrated DNA Technologies Inc.
Construction of plasmids expressing MbtAtb with alternative polyhistidine tags. Ten
pET15b derivatives expressing IPTG-inducible, codon-optimized mbtAtb (mbtAopt) fused to
different polyhistidine tags were constructed (Table S2). The gene mbtAtb was subjected to
analysis for codon optimization for protein expression in E. coli using GenScript
OptimumGeneTM.84 Nucleotide changes suggested by this analysis were introduced into a
synthetic mbtAtb (GenScript Corp.). The synthetic DNA (1,707 bp) included a 5’-end NdeI site
that contained mbtAopt’s start codon and a 3’-end BamHI site following the stop codon. The
synthetic DNA was cloned into pET15b linearized by NdeI-BamHI digestion to generate
pH6MbtAopt, which expresses N-terminally His6-tagged MbtAopt (H6MbtAopt). To construct the
remaining nine pET15b derivatives, the mbtAopt segment of pH6MbtAopt was PCR amplified with
specific primer pairs (Table S3) to generate nine alternative MbtAopt-polyhistidine tag fusions.
The primers incorporated the appropriate tag, a stop codon when needed, and flanking NcoI and
BamHI sites. Each of the amplicons was first cloned into pCR2.1-Topo, then excised from the
pCR2.1Topo construct using NcoI and BamHI, and recloned into pET15b linearized by NcoIBamHI digestion to generate the final nine protein-expression plasmids.
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Pilot protein overproduction, solubility, and binding to Ni-NTA resin experiments.
The ten pET15b derivatives noted above were introduced into E. coli BL21(DE3)pLysS to
generate the ten corresponding protein expression strains. The strains were cultured (50 ml, 220
rpm) at 30°C until an OD600 = 0.5, after which the incubation temperature was reduced to 25°C.
Protein overproduction was induced by addition of IPTG (1 mM) when OD600 reached 0.6. Cells
were harvested by centrifugation 4 h post IPTG addition and resuspended in 630 µl of lysis
buffer. The resuspended cells were then lysed by combining lysozyme treatment (1 mg/ml, 30
min) with the freeze-thaw method.85 Insoluble material was removed from the lysates by
centrifugation (18,000 g, 1 h, 4°C). The cleared lysates were loaded onto Ni-NTA spin columns
(QIAGEN) pre-equilibrated with lysis buffer. The loaded columns were washed (3 × 600 µl)
with wash buffer, and column-bound proteins were eluted (2 × 100 µl) with elution buffer. The
eluates were dialyzed (20 min, 3 x 100 ml of dialysis buffer) at 4°C, and then flash-frozen and
stored at -80 °C. Protein induction, protein solubility (lysate supernatant vs. lysate pellet), and
presence of proteins in column eluates were assessed by SDS-PAGE analysis.83
Overexpression and purification of H10MbtAopt. Mtb MbtA (UniProtKB P71716),
codon-optimized for expression in Escherichia coli with an N-terminal His10 tag (H10MbtAopt),
was overproduced in E. coli BL21(DE3)pLysS carrying plasmid pH10MbtAopt (see Supporting
Information for codon optimization and Tables S1 and S2 for strains and plasmids used in this
study, respectively). The strain was cultured in Luria-Bertani broth83 in Fernsbach baffled flasks
(wide-mouth, 2.8-L capacity) under rotary agitation (220 rpm) at 25 °C to OD600 = 0.3. The
temperature was then reduced to 20 °C and incubation was continued. Protein overproduction
was induced by addition of 1 mM IPTG (isopropyl β-d-1-thiogalactopyranoside) at OD600 ≈ 0.6.
After 16 h of additional incubation, the cultures were chilled on ice and the cells were harvested
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by centrifugation. The cells were resuspended in 20 mL of lysis buffer per liter of culture (50
mM Tris·HCl, pH 8; 10 mM imidazole; 0.5 M NaCl; 20% sucrose; 1 mM β-mercaptoethanol; 1
mM PMSF; 0.1% IGEPAL CA-630). Lysozyme (300 µg/ml), DNase I (100 µg/ml), and MgCl2
(25 mM) were added to the cell suspension, which was then incubated at 0 °C for 30 min and
subsequently subjected to a freeze/thaw cycle for lysis. The lysate was then sonicated (Branson
Ultrasonics Digital Sonifier; 2 × 30 sec, 90% intensity), diluted 1.3 times in lysis buffer,
subjected to high-speed centrifugation (1 h, 20,000 g), filtered (Whatman filter paper, 2.7 µm
pore size), and degassed under reduced pressure. H10MbtAopt was purified from the cleared lysate
by Ni2+-column chromatography using Ni–NTA Superflow resin according to the manufacturer’s
instructions (Qiagen) and an ÄKTA Purifier UPC10 FPLC System (GE Healthcare). The loaded
column (7 mL) was washed with 5 column volumes of wash buffer (75 mM Tris·HCl, pH 8; 20
mM imidazole; 0.5 M NaCl; 5% glycerol), and proteins were eluted using an imidazole gradient
[solvent A: wash buffer; solvent B: elution buffer (75 mM Tris·HCl, pH 8; 0.8 M imidazole; 0.2
M NaCl; 5% glycerol)]. H10MbtAopt eluted at ≈0.36 M imidazole. Fractions containing
H10MbtAopt were then dialyzed (Slide-A-Lyzer Dialysis cassettes; Pierce) into dialysis buffer (25
mM Tris·HCl, pH 8; 0.2 M NaCl; 2 mM DTT; 5% glycerol), aliquoted, flash-frozen, and stored
at –80 °C. Protein fraction quality and protein concentration were determined by SDS-PAGE
(sodium dodecyl sulfate polyacrylamide gel electrophoresis) analysis83 and Bio-Rad Protein
Assay (Bio-Rad Laboratories, Inc.), respectively.
Assay for MbtAtb activity and inhibition. The adenylation activity of H10MbtAopt and
its inhibition were evaluated using a H10MbtAopt-optimized version of the hydroxylamine–7methyl-6-thioguanosine (HA–MesG) continuous, spectrophotometric assay.86 The assay was
carried out in a 96-well plate format as we have recently reported.87 The assay reaction mixture
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was optimized for H10MbtAopt activity. Optimization experiments included evaluation of various
concentrations of Tris·HCl (and pH), hydroxylamine, MesG, ATP, NaCl, MgCl2, glycerol,
reducing agents (DTT and TCEP), and detergent [IGEPAL CA-630, Triton-X100, and CHAPS
(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate)]. Unless otherwise indicated for
specific experiments, the optimized assay reaction mixture contained the following: 50 mM
Tris·HCl, pH 8.0; 3 mM MgCl2; 0.5 mM DTT; 0.1 U purine nucleoside phosphorylase (PNP);
0.04 U inorganic pyrophosphatase (PPT); 450 mM hydroxylamine; 0.4 mM MesG; 1 mM ATP;
300 µM salicylic acid; 0.01% CHAPS buffer; 7.5% ultrapure glycerol; and H10MbtAopt at
concentrations noted for specific experiments. When needed, MbtA inhibitors were added from
10% DMSO stock solutions, with a final DMSO concentration of 1% in both inhibitorcontaining reactions and control reactions (no inhibitor). Reactions were preincubated for 10 min
at 25 °C before being initiated by the addition of either salicylic acid for steady state kinetic
analysis or H10MbtAopt for progress curve analysis. The phosphorolysis of MesG was measured
continuously at either regular 1-min intervals (for steady state kinetic analysis) or 25-sec
intervals (for progress curve analysis) for up to 45 min, at 360 nm and 25°C in a DTX 880
multimode detector microplate reader (Beckman Coulter, Inc.). The concentration of active
H10MbtAopt was validated by active-site titration88 using salicyl-AMS as the reference inhibitor.
The calculated concentration of total H10MbtAopt used in the assays was essentially
indistinguishable from the concentration of active H10MbtAopt determined by active-site titration
(not shown).
ATP
Determination of Km and kcat. Experiments to determine the Km value for ATP (𝐾𝐾m
)

were carried out with ATP in the 1–67.5 µM range (1.5-fold dilution series) and a saturating

salicylic acid concentration of 300 µM. Experiments to determine the Km value for salicylic acid
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sal
(𝐾𝐾m
) were done with salicylic acid in the 0.027–1.3 µM range (1.5-fold dilution series) and a

saturating ATP concentration of 1 mM. H10MbtAopt and MgCl2 were used at 250 nM and 5 mM,
respectively. The spectrophotometric data were analyzed to calculate initial velocity (v0) data. Km
and kcat values were then determined by nonlinear regression analysis of background-corrected v0
versus substrate concentration ([S]) datasets using the Henri–Michaelis–Menten equation with
Vmax replaced by enzyme concentration ([E]) × kcat82 (Eq. 2.1). Prism v6.01 (GraphPad Software,
Inc.) was used for curve-fitting, regression analyses, and statistical analyses of these datasets and
all other experimental datasets generated in this study. The Km and kcat values reported are
averages of two independent experiments.

Eq. 2.1: 𝑣𝑣0 =

[S] [E] 𝑘𝑘cat
[S] + 𝐾𝐾m

Results and Discussion

Cloning, overexpression, and purification of recombinant MbtAtb. MbtAtb is
responsible for formation of the activated salicyl-AMP intermediate during biosynthesis of
MBTS.35 Previous approaches for purification of recombinant MbtAtb expressed in E. coli have
achieved low yields (0.1–2 mg/L), insufficient for large scale studies of the protein as a
molecular target of the salicyl-AMS inhibitor and structural analogues.35, 64, 65 These
inefficiencies were thought to be due to low expression, poor solubility, inefficient affinity tag
removal, and the need for multiple purification steps.35, 64, 65 We sought to overcome these
challenges, making MbtAtb more readily available for our SAR inhibition studies.
We first carried out codon optimization, which led to changes in 322 of the 566 codons of
mbtAtb (Figure 2-1). GenScript’s analysis rated the native mbtA gene with a 0.41 Codon
Adaptation Index (CAI) based on codon usage frequency in the E. coli host, in which a CAI of
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Figure 2-1. Nucleotide sequence alignment of mbtAtb and mbtAopt.
Boxed nucleotides indicate changes in mbtAopt relative to the native mbtAtb. The native
mbtAtb (Rv238435) was subjected to analysis for gene optimization for protein expression in E.
coli. The analysis identified 36% and 14% of the codons in mbtAtb being used <70% and <10%
of the time, respectively, by E. coli. The analysis recommended 341 nucleotide changes (shown).
The changes were incorporated in mbtAopt. Adapted from [74].
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1.0 is considered ideal and a rating > 0.8 is good for expression. GenScript defines low
frequency codons as those used < 30% of the time by the host and identified 36% of the 566
amino acids in MbtA as being used <70% of the time and as many as 14% being used less than
10% of the time by E. coli. While the overall GC content was 69%, at least 5 stretches of 60+ bp
peaked above the appropriate 70% GC content, which can adversely affect transcriptional and
translational efficiency. The final gene sequence after optimization had a CAI rating of 0.96 with
all 566 amino acids being used more than 80% of the time by the host and a final GC content of
65% after removing the problematic 60+ bp regions discussed. The algorithm also adjusted direct
repeats found close together and potentially challenging inverted and dyad repeats found in the
sequence.
We then evaluated ten different polyhistidine affinity tag strategies (viz. alternative tag
lengths and locations, double tags, and a tandem tag) for the codon-optimized MbtAtb (MbtAopt)
(Figure 2-2). This included unconventional tags that have been shown to be advantageous with
other problematic recombinant proteins.75, 76 We opted to test 10 different iterations of histidine
tagging including six, eight, and ten histidine residues as well as the double-hexahistidine tag in
hopes of increasing binding affinity to the Ni-NTA coloum.75, 76 Tags were included on the Nterminus or C-terminus alone as well as on both termini at the same time, except for the double
hexahistidine tag which was only incorporated on the N-terminus. Initial testing ruled out the use
of C-terminally tagged enzymes as no expression was seen after induction with IPTG

.

Interestingly, MbtAopt expression after IPTG induction was only seen when a N-terminal tag was
included. Ultimately, SDS-PAGE gels showed comparable expression and elution from a smallscale Ni-NTA spin column at a single high imidazole concentration (not shown). The N-terminal
decahistidine tagged MbtAopt (H10MbtAopt) was chosen to advance towards large scale
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purification. This decision was made taking into consideration a balance between increasing
binding affinity by tag length without compromising enzymatic activity with too many additional
residues. In addition, preliminary experiments with a N-terminal hexahistinde tagged MbtAopt
demonstrated promising catalytic activity, while the effect of a C-terminal tag was unknown. In
the end, the final 10 L purification of H10MbtAopt yielded 7.8 mg/L of pure protein (Figure 22B), a noteworthy improvement from previously reported methods.
Overall, the codon and tagging optimizations shortened the purification protocol by
eliminating the need for tag cleavage and size exclusion chromatography, produced purified
H10MbtAopt with purity levels sufficient for downstream assessment of its kinetics and inhibition
(Figure 2-2B), and achieved final yields of up to ≈8 mg/L. This represents a 4-fold increase
relative to the highest yield previously reported for MbtAtb.65

Figure 2-2. Polyhistidine tagged MbtAopt proteins.
(A) Different polyhistidine tag strategies evaluated with MbtAopt. (B) Sodium dodecyl sulfate
polyacrylamide gel electrophoresis analysis. Lane 1, molecular marker standards. Lane 2,
purified H10MbtAopt (77 µg loaded). The gel (12.5%) was stained with GelCode Blue Stain
Reagent (Thermo Fisher Scientific) for protein visualization. Adapted from [74].
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Validation of H10MbtAopt activity and inhibition by salicyl-AMS in the HA–MesG
kinetic assay. The larger decahistidine tag of H10MbtAopt could potentially hinder its enzymatic
activity and/or its inhibition by salicyl-AMS as a potent tight binding inhibitor.64 Therefore, we
sought to first validate the activity of H10MbtAopt and its inhibition by salicyl-AMS. The Quadri
and Aldrich labs have previously used a traditional ATP–32PPi isotope exchange (ATP-PPi) assay
to characterize the adenylation activity of MbtAtb35 and its inhibition by salicyl-AMS.64 This
assay measures the reverse of the adenylation reaction (formation of pyrophosphate) and is
disadvantaged by its end-point nature, need for radiolabeled reagents, and low-throughput
format. To overcome this, we explored the adoption of a continuous, spectrophotometric HA–
MesG assay that measures the forward direction of the adenylation reaction in a kinetic nature.86
The HA-MesG assay has recently been used to characterize several adenylation enzymes,

Figure 2-3. Preliminary dose-response experiments demonstrating inhibition of H10MbtAopt.
The data shown represents one of two independent dose-response experiments using H10MbtAopt
at 250 nM. The IC50 value was calculated by fitting the dose-response dataset (•) to the
sigmoidal equation vi⁄v0 = b + a - b⁄1 + ( [I]⁄IC50 )s, where vi and v0 are initial reaction velocities
of inhibitor-containing reactions and DMSO-containing reaction controls (no inhibitor),
respectively, a and b are the top and bottom of the sigmoidal curve (solid line; R2 values ≥
0.988), respectively, and s is the Hill coefficient. Adapted from [74].
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including MbtAtb.86 We sought to initially characterize inhibition of H10MbtAopt by salicyl-AMS
with the assay’s original format.
Encouragingly, the first assessment of H10MbtAopt in the HA–MesG assay, and its
inhibition by salicyl-AMS, demonstrated the expected adenylation enzyme activity and a potent
tight-binging inhibitor behavior (i.e. IC50 ≈ ½ [E]) (Figure 2-3). Additionally, the activity was the
first demonstration that the decahistidine tag did not have a detrimental effect on H10MbtAopt
activity.
Table 2-1. Effect of potential trace compounds on the MbtAtb signal in the HA-MesG assay.
Adapted from [74].
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As this was the first time MbtA inhibition was assessed in the HA-MesG assay, we then
investigated whether salicyl-AMS had any inhibitory effect on the pyrophosphatasephosphorylase (PPT-PNP) secondary enzymes included in the reaction. Ultimately, salicyl-AMS
did not affect the PPT-PNP coupling system when tested at up to 40 µM, which is 10-fold
greater than the maximum concentration used. We also evaluated whether four salicyl-AMS
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related fragments (Table 2-1), potentially coming from hydrolytic degradation or from
contamination after synthesis, could interfere with MbtA activity in the HA–MesG assay. Our
results show that only salicyl-sulfamate depressed the H10MbtAopt-dependent signal, but only at
concentrations far above what is used when analyzing salicyl-AMS inhibition (Table 2-1).
Therefore, inhibition by an off-target effect of salicyl-AMS or by potential trace contaminants
will not confound assay results. To our knowledge, this is the first evaluation of inhibitors of a
salicyl-AMP ligase using the HA–MesG assay.

Figure 2-4. Improvement of H10MbtAopt activity in the optimized HA-MesG assay.
The optimization of the assay led to several changes in reaction composition (A) and a
≈3-fold increase in H10MbtAopt activity (B). Adapted from [74].
Initial experiments were carried out using the generic HA–MesG assay conditions for a
range of enzymes with adenylation activity.86 Since its initial report, several groups have pursued
optimization of the assay conditions to increase the performance of their enzyme of interest.89-92
For a challenging enzyme such as MbtA, these optimizations could reduce the amount of protein
added to the assay and conserve the precious reagent. Thus, the assay was optimized for
H10MbtAopt before further characterizing its kinetic parameters or inhibition by other analogues.
Concentrations and pH of assay components were systemically modified and several additives
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known to stabilize reactions were assessed.93 Concentration optimization of hydroxylamine,
ATP, MgCl2, MesG, and DTT as wells as addition of glycerol and CHAPS detergent achieved a
≈3-fold increase in H10MbtAopt activity (Figure 2-4). These alterations allowed for a 4-fold
decrease in MbtA concentration in the assay from that used in the original report of the assay.86
This alteration conserved precious protein while maintaining sufficient activity for analysis of
H10MbtAopt kinetic parameters and inhibition.
Steady-state kinetic parameters of H10MbtAopt. To further assess the fidelity of the
new recombinant H10MbtAopt enzyme we determined its Michaelis−Menten kinetic parameters
using the optimized HA–MesG assay (Figure 2-5). Kinetic analysis with salicylic acid as the
sal
sal
and 𝑘𝑘cat
values of 0.31 ± 0.003 µM and 0.90 ± 0.06 min-1,
variable substrate revealed 𝐾𝐾m

ATP
respectively. With ATP as the variable substrate, the 𝐾𝐾mATP and 𝑘𝑘cat
values were 13.0 ± 1.3 uM

and 1.16 ± 0.04 min-1, respectively. Because kcat is related to the turnover of the substrates
together to the product, agreement of the two kcat values indicates consistency between

evaluations of both substrates and establishes reliability of the experimental approach. Notably,
the average kcat value of H10MbtAopt (≈1 min-1) is comparable to those of the related 2,3dihydroxybenzoate adenylation enzymes involved in the biosynthesis of several aryl-capped
siderophores,94 including E. coli EntE (≈1 min-1), Acinetobacter baumannii BasE (≈1 min-1),
and, to some extent Vibrio cholerae VibE (≈0.2 min-1), in conjunction with their own DHBA
substrate.86 The relatively low kcat values of these ligases may be attributed to the lack of
interaction between the ligase and its downstream protein partner, as hydroxylamine acts as a
surrogate acyl-acceptor in the HA–MesG assay. The phosphopantetheinylated carrier protein
partner is thought to be needed to trigger the rotation of the ligase’s C-terminal domain to
facilitate the transfer step, and its absence in the assay may account for this low rate.95
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ATP
This was the first time the 𝐾𝐾mATP and 𝑘𝑘cat
values were determined in the forward

direction of the biosynthetic pathway, as all previous determinations were done with the ATPPPi assay. The initial report of a different recombinant MbtAtb in the generic HA–MesG assay
sal
sal
calculated a 𝐾𝐾m
value identical to the one reported here, but a 𝑘𝑘cat
value ≈3-fold lower than the
sal
one determined by our analysis.86 It is tempting to believe that the higher 𝑘𝑘cat
value found

herein might be due to our optimized assay conditions, which also increased enzymatic activity
3-fold. The Km values calculated for His10MbtAopt has ≈40-fold higher affinity for salicylic acid
than for ATP. This finding is in agreement with the previously reported 65- and 32-fold
preference for salicylic acid found with MbtAtb and YbtE, a salicylate adenylation enzyme with
45% amino acid identity from Y. pestis.64, 65 Interestingly, these KATP
and Ksal
m
m values previously
measured with the ATP-PPi assay were 10–20 times larger than those determined here,
indicating an increase in substrate affinity in the optimized HA–MesG assay.

Figure 2-5. Michaelis−Menten kinetic parameters for H10MbtAopt.
The v0 vs. [S] datasets were generated using salicylic acid (A) or ATP (B) as the variable
substrate. Each plot shown is representative of two independent experiments. The datasets (•)
were fitted to Eq. 1 to generate the solid line (R2 values ≥ 0.993). The kinetic parameters
indicated are mean values ± SEM of n = 2 independent experiments. Adapted from [74].
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Conclusions
We have performed a comprehensive analysis of the salicylate adenylation enzyme
MbtA. We successfully optimized our purification approach 3-fold and the HA-MesG assay 3fold from that previously reported. These improvements allows for a 4-fold reduction of enzyme
in the assay format and the kinetic analysis of MbtA inhibitors. This new assay format is also a
more high-throughput system for the evaluation of inhibitors than the previously used ATP-PPi
exchange assay.
Ultimately, codon optimization successfully helped expression of MbtA, the newly
modified H10MbtAopt variant yielded the highest amount of protein reported, and the new
decahistidine tag did not compromise MbtA activity. Our initial studies demonstrated that the
enzyme was active and the salicyl-AMS inhibitor maintained its tight binding inhibitor
sal
sal
characteristics in the HA-MesG assay. We successfully demonstrated 𝐾𝐾m
and 𝑘𝑘cat
values that

ATP
coincide with those previously reported. For the first time, we demonstrated the 𝐾𝐾mATP and 𝑘𝑘cat

values in the HA-MesG assay, which demonstrated a lower affinity for ATP than salicylic acid,
similar to previous reported using the ATP-PPi assay. These optimizations and validations of the
protein target and enzymatic assay set the stage for a comprehensive analysis of MbtA inhibition
kinetics.
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CHAPTER 3: KINETIC ANALYSES OF THE SIDEROPHORE
BIOSYNTHESIS INHIBITOR SALICYL-AMS AND ANALOGUES AS
MbtA INHIBITORS
Introduction
Previously, the Quadri and Tan labs developed the first-in-class nucleoside antibiotic
salicyl-AMS (Figure 1-9A)64 as a salicyl-AMP intermediate mimetic inhibitor of the enzyme
MbtA of Mtb (MbtAtb, Figure 1-9B).35 Salicyl-AMS is a potent, selective, tight-binding inhibitor
(TBI) of MbtAtb, as well as other salicylate adenylation enzymes from pathogenic bacteria,64
including YbtE from Yersinia pestis96 and PchD from Pseudomonas aeruginosa.97 The Quadri
and Tan labs have shown that salicyl-AMS inhibits the biosynthesis of MBTS in Mtb and
restricts the growth of the pathogen with much greater potency under iron-limiting conditions,64
where production of MBTS is crucial for iron acquisition. In all, this work provided a proof of
concept for the druggability of salicylate adenylation enzymes, validated pharmacological
inhibition of siderophore biosynthesis as a new mechanism of antibiotic action, and established
salicyl-AMS as a first-in-class antibacterial lead compound for the development of TB drugs
targeting siderophore biosynthesis. Subsequent studies by Aldrich and coworkers confirmed the
inhibitory activity of salicyl-AMS against MbtAtb and Mtb, demonstrated that the inhibitor is not
cytotoxic against mammalian cells, and provided extensive in vitro structure–activity
relationship (SAR) analysis for inhibition of MbtAtb biochemical activity and Mtb growth using a
wide range of salicyl-AMS analogues.65-67, 69-73, 98, 99
These novel antibacterials are considered bisubstrate inhibitors due to their occupation of
both active sites of the two MbtA substrates, salicylic acid and ATP.71 The high potency of
salicyl-AMS is due, in part, to the small entropy barrier to binding of the intermediate species
salicyl-AMP.71 In the case of MbtA, delivery to the separate carrier partner MbtB, rather than an
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attached carrier protein domain, is unique among NRPSs.71 If the two were attached, as seen in
many other adenylation domain enzymes, delivery to the carrier domain is entropically favored
due to proximity.71 This detachment further demonstrates the importance of the tight binding
nature of MbtA to the Sal-AMP intermediate, and lends to the potent activity of the Salicyl-AMS
intermediate mimic inhibitor.
With any given set of new lead compounds, it is important to pursue a detailed analysis
of their efficacy against the MbtA target. The classical approach to in vitro analysis of inhibitor
potency focuses primarily on the equilibrium dissociation constant (KD) of ligand binding
affinity. This measure of binding affinity is called the inhibition constant (KI) when describing an
inhibitor in particular. The Ki is determined by the relationship between the dissociation and
association rates of the enzyme-inhibitor complex (𝑘𝑘off ⁄𝑘𝑘on ).

The drug and enzyme concentrations in the classical “closed-system” in vitro analysis are

constant, but this is not representative of biological systems, which are instead considered
“open” due to drug and enzyme concentrations being in a continuous flux.100 This flux defies
what we know about inhibitors based on equilibrium binding affinities, which are related to both
the association (kon) and dissociation (koff) rates.100 In closed systems the kon is constant, but in
open systems it can be affected by the concentration flux caused be things such as intestinal
adsorption, tissue distribution, and diffusion rate.100 These factors can greatly limit drug efficacy.
Conversely, the koff is generally considered independent of these factors and entirely dependent
on the drug-enzyme binding pocket interaction.100
Evidence exists that modifications to inhibitor structure may change both koff and kon
inversely without a significant change in Ki.101, 102 Additionally, improvements in Ki could be the
result of enhancements for only one of the two binding rates.101, 102 As a result, traditional Ki
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analysis might not pick up on important improvements in koff values. This further stresses the
importance of narrowing focus to individual binding rates rather than equilibrium constants, like
the Ki. Despite the recent realization of binding kinetics importance, their understanding alone is
not enough to predict in vivo efficacy. Important factors other than drug-target binding include
drug concentration in plasma and target tissue, nonspecific binding, competition with substrates
of the target, and target turnover.101 Still, a comprehensive understanding of these biological
factors along with a knowledge of the koff can lead to better selection of lead compounds to
advance to the next level of testing in the drug development pipeline.
In attempt to improve the correlation between in vivo and in vitro drug potency, the focus
should be mainly on the koff of the enzyme-inhibitor complex. The general term residence time
(tR) is essentially the dissociative half-life of the receptor-ligand complex, and is simply defined
as the reciprocal of the koff.103 The investigation of the inhibitor tR attempts to predict a nonequilibrium model of drug action, where ligand can vary with time between dosing based on a
variety of biological factors. A tR analysis has proven to parallel the in vivo drug potency better
100
than analysis of classical equilibrium parameters (e.g. IC50, Kapp
Though dissociation of
i , Ki).

the drug-target complex is important, measurement is often limited by experimental design and
throughput.103 More important than determination of exact kinetic parameters (koff, tR) is the
ability to design experiments determining the difference in sets of analogues simultaneously, as
comparison between separate datasets is limited.101
We report herein detailed in vitro evaluation of salicyl-AMS , two novel salicyl-AMS
analogues designed to probe new SAR alterations, and six of the most potent analogues reported
previously by others.66 We used for the first time a continuous, spectrophotometric adenylation
assay (HA-MesG) to measure MbtA inhibition, allowing for a more high-throughput study of
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inhibition kinetics. The inherent inhibition constant (Ki) for MbtA and salicyl-AMS has never
been calculated due to restrictions of the low-throughput ATP-PPi exchange assay and the TBI
nature of the compound. To these ends, we measured the intrinsic inhibition (Ki) of MbtAtb by
salicyl-AMS, analyzed the mechanism of inhibition of the nine inhibitors, and compared the
app

inhibitors’ kinetic parameters (Ki , kapp
on , koff, and tR) to expand existing SAR knowledge.
Materials and Methods
Synthesis of MbtA inhibitors. All synthesis was designed and performed by our
collaborators in the Derek Tan lab in Memorial Sloan Kettering Cancer Center, as reported.74
Salicyl-AMS (1)64 was synthesized by WuXi AppTec (Shanghai, China). Salicyl-2´-dAMS (2),65
salicyl-2-Ph-AMS (3),71 salicyl-2-PhNH-AMS (4),71 salicyl-AMSN (4a),72 salicyl-6-N-Me-AMS
(5a),71 and salicyl-6-N-c-Pr-AMS (5b),71 were synthesized as previously described. SalicylAMSNMe (4b) was synthesized in seven steps from 6-N-Boc-2´,3´-isopropylideneadenosine.
Salicyl-6-MeO-AMSN (6) was synthesized in 10 steps from inosine.74
Determination of Ki. The Ki of salicyl-AMS (1) for H10MbtAopt was determined by
Morrison analysis for TBIs.88, 104 Two Ki values were determined using two experimental
modalities with respect to substrates. One modality used variable, saturating concentrations of
ATP (0.86–6.5 mM range) along with a constant, saturating concentration of salicylic acid (300
µM). The other modality used variable, saturating concentrations of salicylic acid (30.6–310 µM
range) along with a constant, saturating concentration of ATP (6.5 mM). H10MbtAopt and MgCl2
were used in the assays at 250 nM and 15 mM, respectively. Salicyl-AMS (1) was tested using a
50–1,040 nM range. The range was covered using a 2-fold dilution series format for sections A
and C of the dose-response curve and a 1.2-fold dilution series format for section B (“elbow”) of
the curve as recommended.88, 105 The spectrophotometric data were used to determine fractional
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initial velocities (vi/v0), where vi is the initial velocity with inhibitor and v0 is the initial velocity
app

with no inhibitor (DMSO controls). 𝐾𝐾i

values were calculated by Morrison analysis of

background-corrected vi/v0 versus logarithm of inhibitor concentration ([I]) datasets using Eq.
app

3.1, as described88. A Ki value was then obtained from each of the two datasets of 𝐾𝐾i

values

vs. [S] as the y-intercept of the linear regression of the data fitted to Eq. 3.2.104 Each of the two
app

Ki values reported was calculated from the average of 𝐾𝐾i

datasets generated from three

independent experiments.

app
app
�[E] + [I] + 𝐾𝐾i � − �([E] + [I] + 𝐾𝐾i )2 − 4 [E] [I]
𝑣𝑣i
= 1 −
Eq. 3.1:
𝑣𝑣0
2 [E]
app

Eq. 3.2: 𝐾𝐾i

= 𝐾𝐾i (1 +

[S]
)
𝐾𝐾m

app

Progress curves and determination of kinetic parameters 𝐾𝐾i

app

, 𝑘𝑘on , koff, and tR.

Reactions were pre-incubated for 10 min before being initiated by the addition of H10MbtAopt (1
µM). The concentration range at which each inhibitor was tested was selected empirically by
pilot experiments (not shown). The ranges were as follows: 4,000–1,041 nM range (1.4-fold
dilution series) for 1, 4a, 4b, 5a, 5b, and 6; 2,000–1,157 nM range (1.2- and 1.3-fold dilution
series combination) for 3a; 3,000–1,366 nM range (1.3- and 1.5-fold dilution series combination)
for 3b; and 2,857–1,041 nM range (2.2- and 1.4-fold dilution series combination) for 2. As done
in similar studies,106, 107 the background-corrected spectrophotometric data were fitted to Eq. 4.108
In Eq. 4, A is the absorbance at time t, vps is the pre-steady state initial velocity, vs is the steadystate velocity at equilibrium, and kobs is the rate constant for progression to steady state. The
datasets of vs versus [I] derived from the progress curves were fitted to Eq. 3.1 to calculate the
app

Ki

values. The kobs values were determined with Eq. 3.3 for each inhibitor concentration and
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then used to calculate the dissociation rate constant (koff) values using Eq. 3.4,109 as previously
app

reported.110, 111 Subsequently, 𝑘𝑘on values were determined using Eq. 3.5 and the calculated koff
app

and the 𝐾𝐾i values.109 Residence time (tR) values were calculated as the reciprocal of the koff

value. To assess the inhibition mechanisms of the inhibitors, kobs values versus [I] datasets were
plotted and fitted to Eq. 3.6.109 Each kinetic parameter reported is the average derived from a
minimum of five independent experiments. Pearson correlation analysis between kinetic
parameters was carried out using the statistical analysis package in Prism v6.01. Pearson
correlation coefficients (PCCs) with Student’s t-test p values ≤0.05 were considered statistically
significant.

Eq. 3.3: 𝐴𝐴 = 𝑣𝑣s 𝑡𝑡 +

𝑣𝑣ps − 𝑣𝑣s
[1 − 𝑒𝑒(− 𝑘𝑘obs 𝑡𝑡)]
𝑘𝑘obs

Eq. 3.4: 𝑘𝑘off = 𝑘𝑘obs
app

Eq. 3.5: 𝑘𝑘on =

𝑣𝑣s
𝑣𝑣ps

𝑘𝑘off

app

𝐾𝐾i

Eq. 3.6: 𝑘𝑘obs = 𝑘𝑘on [I] + 𝑘𝑘off

Results and Discussion
Determination of intrinsic Ki for salicyl-AMS with H10MbtAopt. The Ki value of
salicyl-AMS for inhibition of MbtAtb has not been reported. Though the Ki of MbtA and a
carbocyclic salicyl-AMS analogue was reported to be 0.038 ± 0.007 nM, the results were
confounded by the TBI characteristics of these drugs.65 Determination of the salicyl-2-phenylAMS analogue’s Ki was also complicated by its tight-binding behavior.71 Thus, we set out to
determine the Ki value for H10MbtAopt inhibition using the optimized HA–MesG assay. We
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followed the Cheng analysis approach previously applied to determine the Ki value of salicylapp

AMS for inhibition of YbtE, requiring enzyme inhibition (e.g. IC50 or Ki ) to be measured over
a range of substrate concentrations.64, 104 Salicyl-AMS is a tight binding inhibitor of H10MbtAopt,
app

as demonstrated in Chapter 2, which calls for measurement of Ki

by the Morrison analysis due

to its stronger distinguishing power over IC50 values.88 Because MbtAtb requires two substrates
to undergo the adenylation reaction, two Ki values were independently calculated over a range of
either ATP or salicylic acid concentrations while the other substrate remained constant.
app

For both approaches, Ki values increased linearly with increasing concentration of
substrate (Figure 3-1), indicative of a competitive inhibition mechanism for salicyl-AMS with
respect to both MbtAtb substrates.104 This mechanism of inhibition was also seen when assessing
the Ki of the carbocyclic analogue in the ATP-PPi assay.65 The Cheng analysis of competitive
app

inhibition results in a Ki value equal to the y-intercept of the linear fit lines when Ki

values are

plotted as a function of [substrate].104 The values determined were 0.76 ± 0.43 nM for KATP
and
i
1.04 ± 0.48 nM for Ksal
i (Figure 3-1). Encouragingly, these intrinsic Ki values of salicyl-AMS are
essentially the same number, demonstrating correspondence between the two evaluations with
respect to substrate and highlighting the robustness of the methodological approach. Notably, the
average Ki value of 0.9 nM is also comparable to our previously reported Ki for salicyl-AMS’s
inhibition of Y. pestis YbtE (0.7 nM).64 These results demonstrate that salicyl-AMS is a potent
inhibitor of H10MbtAopt with sub-nM Ki values.
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Figure 3-1. Ki value of salicyl-AMS for H10MbtAopt inhibition.
Two Ki values were independently calculated using two approaches having opposite relationship
value (A) and Ksal
of constant versus variable substrate. The KATP
i
i value (B) were calculated
app
from datasets of 𝐾𝐾i values vs. ATP and salicylic acid concentration, respectively, as the yintercept of the linear regression of the data (•) fitted to Eq. 3 (solid line; R2 values ≥ 0.6). The Ki
app
values indicated were calculated from the average of 𝐾𝐾i
vs. variable substrate datasets
app
generated from three independent experiments. Error bars on 𝐾𝐾i data points represent SEM of
n = 3. Adapted from [74].
Selection of salicyl-AMS analogues for further evaluation. Six of the most potent
previously reported salicyl-AMS analogues were selected for a detailed in vitro analysis of
app

several kinetic parameters (Ki , kapp
on , koff, and tR) (Figure 3-2). These analogues contain
modifications in different regions of the lead compound, including deletion of the ribose 2´hydroxyl group (salicyl-2´-dAMS, 2),65 replacement of the ribose 5´-oxygen (salicyl-AMSN,
4a),72 and substitutions of the adenine ring at the C2 position (salicyl-2-Ph-AMS, 3a; salicyl2-NHPh-AMS, 3b)71 and 6-amino group (salicyl-6-N-Me-AMS, 5a; salicyl-6-N-c-Pr-AMS,
5b).71
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Figure 3-2. Structural differences between salicyl-AMS (1) and its various analogues
evaluated herein.
Analogues include modifications to the AMS moiety (dotted line box). Me, methyl; Ph, phenyl;
c-Pr, cyclopropyl. Adapted from [74].
Our collaborators in the Derek Tan lab at Memorial Sloan Kettering Cancer Center
designed and synthesized two analogues to further expand the existing SAR analysis (Figure 32). Salicylate adenylation enzymes are members ofWDQ the ANL family (acyl-CoA synthetase,
non-ribosomal peptide synthetase adenylation domain, luciferase)95 that bind their substrates in
an unusual bent cisoid conformation (Figure 3-3A).112, 113 Introduction of a 5´-N-methyl
substituent in salicyl-AMSN as a turn element in salicyl-AMSNMe (4b; Figure 3-2) was
incorporated to promote this conformation and potentially improve binding efficiency.
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Figure 3-3. Design rationales for new salicyl-AMS analogues.
(A) Cocrystal structure of 2,3-dihydroxybenzoyl-AMP (DHB-AMP, gray) bound in the active
site of the DHBA adenylation enzyme Bacillus subtilis DhbE (cyan and white, PDB: 1MDB),112
illustrating pharmacophoric cisoid binding conformation.113 Salicyl-AMSNMe (4b) is designed
to promote this cisoid binding conformation. (B) Structures of previously reported inosine
analogue salicyl-IMS (11) and dimethylated analogue salicyl-6-N,N-diMe-AMS (12), both of
which are weak MbtAtb inhibitors,71 presumably due to loss of hydrogen-bonding interaction
with the main-chain carbonyl oxygen of MbtAtb V352 (DhbE V329). Salicyl-6-MeO-AMS (6) is
designed to remove this hydrogen-bonding interaction without introducing a proton at N1 via
tautomerization (cf. 11) and without introducing a potential steric clash with V352 (cf. 12).
Adapted from [74].
In addition, previous reports by Aldrich indicate that small 6-amino substituents could be
accommodated in salicyl-AMS analogues 5a and 5b without dramatic loss of activity.71, 114, 115 In
contrast, however, the corresponding inosine analogue (11, Figure 3-3B) with replacement of the
app

amino group with an oxygen was a poor MbtAtb inhibitor with no antimicrobial activity (Ki
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=

800 nM; Mtb MIC > 100 µM).71 As a result of this finding, it was proposed that a hydrogenbond donor may be required at the C6-substituent position to interact with the main-chain
carbonyl oxygen of MbtAtb V352.115, 116 This was further supported by the finding that the
app

adenine 6-N,N-dimethyl analogue (12) was also a weak inhibitor (Figure 3-3B; Ki

= 380 nM;

Mtb MIC = 50 µM). However, the inosine also introduces a proton at the neighboring nitrogen in
analogue 11 while the modification of 12 introduces additional steric constraints. Thus, to probe
this SAR further, we introduced a 6-methoxy substituent in salicyl-6-MeO-AMSN (6; Figure 32), which lacks the C6-substituent hydrogen-bond donor but maintains the deprotonated
neighboring nitrogen and introduces similar steric constraints to the active 6-N-methyl analogue
5a. Initial attempts by our collaborators to synthesize the corresponding sulfamate linker

Figure 3-4. Schematic representation of static, slow-onset inhibition progress curves.
The static, slow-onset mechanism of enzyme inhibition displays characteristic progression of
activity in presence of drug. Each black line tracks the formation of product by an enzyme when
in the presence of various concentrations of inhibitor, or no inhibitor. The initial linear phase has
a slope equal to the uninhibited control, representing the pre-steady state velocity vps, which is
constant for different [inhibitor] for static inhibitors (Figure 3-5) (red). The final linear phase
after reaching equilibrium has a slope representing the steady-state velocity (vs), which decreases
as [inhibitor] increases (purple). The connecting phase joins the two linear phases and
corresponds to a rate constant (kobs) describing the rate of change between the other two states
(blue).
59

analogue, salicyl-6-MeO-AMS, were thwarted by product instability. This necessitated the use of
the more stable sulfamide linker for 6, as also seen in 4a.72
Progress curve analysis of kinetics of MbtAtb inhibition by salicyl-AMS and
analogues. With the new analogues of interest (4b and 6), we aimed to evaluate their inhibition
activity against MbtAtb alongside lead compound salicyl-AMS (1) and the six previously
reported analogues (2, 3a, 3b, 4a, 5a, & 5b). We determined and compared the kinetics of their
H10MbtAopt inhibition by progress curve analysis, lending insight on the time dependence of the
onset of H10MbtAopt inhibition and revealing more detailed information about their mechanisms
of inhibition. Progress curves of the entire inhibitor set displayed a nonlinear progression of
H10MbtAopt inhibition. The characteristic three phases of a time-dependent, slow-onset
mechanism of inhibition were observed (Figure 3-5) including an initial linear phase with a slope
corresponding to a pre-steady-state velocity before reaching equilibrium (vps), a final linear phase
after reaching equilibrium with a slope representing the steady-state velocity (vs); and an
exponential phase that connects the two linear phases that corresponds to a rate constant (kobs)
describing the approach to the steady state (Figure 3-4).108, 109 In contrast, progress curves for
uninhibited reactions (DMSO controls) showed the expected linear profile of MbtAtb steady-state
kinetics (Figure 3-5). These results demonstrate that salicyl-AMS (1) and the inhibitor set are
slow-onset inhibitors of H10MbtAopt, which is a common trait among TBI and allows for
extrapolation of data to determine koff values.109 The results also provide the first indication that
salicyl-AMSNMe (4b) and salicyl-6-MeO-AMSN (6) potently inhibit MbtAtb, signifying
modifications were not detrimental to their activity.
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Figure 3-5. Representative data for the kinetics of time-dependent inhibition of H10MbtAopt.
The plots show the progress curves for MbtAtb inhibition by different concentrations of
inhibitors. The inhibitor number is indicated on the upper left corner of the plot. Each plot is
representative of at least five independent experiments. The solid lines represent curve fitting to
the dataset (•) using Eq. 4 to extract kobs values. The R2 values for ≈270 progress curves
generated were in the 0.789–0.999 range, with an average of 0.985 and a median of 0.995,
demonstrating excellent fit for the large majority of the curves. Adapted from [74].
Fitting progress curves to the integrated rate equation (Eq. 3.3) for slow-onset inhibitors
allow for calculation of and vps, vs, and kobs values for each independent inhibitor concentration
using nonlinear regression analysis (Figure 3-5).108, 109 With the vps, vs, and kobs values in hand,
the dissociation rate constant (koff) can be calculated for each progress curve using Eq. 3.4.109, 110
The relationship between kobs values and inhibitor concentration can be used to better understand
specific mechanisms of inhibition (Figure 3-6). In the case of this inhibitor set, the linear trends
(Figure 3-7) indicate a static, slow-onset mechanism of inhibition for the entire inhibitor set.109
These results indicate for the first time that salicyl-AMS (1) exhibits this mechanism of
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Figure 3-6. Mechanisms of enzyme inhibition.
(A) A cartoon illustrating the three widely accepted interactions between enzyme and inhibitor.
The simple, one-step static model of interaction is depicted in the middle, in which the enzyme’s
active site is structurally fixed and affinity is dictated solely by interactions with inhibitor.103 The
induced-fit model is shown to the left, in which free enzyme can bind inhibitor sub-optimally in
an encounter complex, but the act of binding itself causes a conformational change of the active
site for optimal complementarity.103 The conformational selection model is shown to the right, in
which the free enzyme exists in multiple conformers, of which only one is capable of binding the
inhibitor with high affinity.103 (B) Theoretical plots representing the relationship between kobs
and [inhibitor] for the three mechanisms of inhibition.117 Adapted from [103, 117].

inhibition with the MbtAtb target, and is the first time this is shown for any salicylate adenylation
enzyme. Recently, salicyl-AMS (1) was shown to have this static, slow-onset mechanism with
the 2,3-dihydroxybenzoate adenylation enzyme EntE from E. coli (40% sequence identity with
MbtAtb) using an assay specific for the protein target.106 This reinforces our overall conclusions
about the inhibitory mechanism of this set of inhibitors and further supports our use of the HAMesG assay.

62

Figure 3-7. Trends of the rate of progression to steady state indicate static, slow-onset
mechanisms of inhibition.
The datasets show the dependence of the extracted kobs on the concentration of the inhibitors. The
datasets (•) were fitted to Eq. 7 to generate the solid lines (R2 values ≥ 0.847). kobs datapoints
represent mean values ± SEM of n ≥ 5 independent experiments. Adapted from [74].
Determination of kinetic parameters for inhibition of H10MbtAopt by salicyl-AMS
and analogues. A comprehensive understanding of MbtAtb inhibition by salicyl-AMS (1) and
our analogues of interest (2–6) warrants a side-by-side comparison of both their steady state and
app

non-equilibrium kinetic parameters, including 𝐾𝐾i

app

, 𝑘𝑘on , koff, and tR. We first assessed whether

any of the analogues had an off-target effect on the PPT-PNP coupling system of the assay, as

was investigated for salicyl-AMS in Chapter 2. None of the analogues affected the PPT-PNP
coupling system when tested at up to 40 µM, which is 10-fold greater than the maximum
concentration used (Table 3-1), thus clearing the way for their evaluation in the HA-MesG assay.
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Table 3-1. Effect of MbtA inhibitors on the activity of the PPT-PNP coupling system of the
HA-MesG assay. Adapted from [74].

Inhibitor

Fractional velocity vi/v0
[inhibitor] = 4 µM

Fractional velocity vi/v0
[inhibitor] = 40 µM

1

0.96

1.01

2

0.96

0.96

3a
3b
4a

0.97
0.99
0.94

0.98
1.02
0.96

4b

0.95

0.89

5a
5b
6

0.99
1.00
1.00

0.96
1.00
1.00

We then assessed whether the TBI behavior of the previously reported analogues (2, 3a,
3b, 4a, 5a, 5b), as per the ATP-PPi assay,65, 71-73 was recapitulated under the conditions of the
HA–MesG assay and whether the novel analogues (4b & 6) shared this potent activity. When
assessing the inhibitor concentration to achieve 50% inhibition of activity (IC50) in steady state
conditions, TBI are characterized by their IC50 values being ≈½ [E], due to their nearly 1:1 ratio
of enzyme to inhibitor binding. All inhibitors, including novel analogues 4b and 6, displayed
these TBI inhibitor characteristics (Table 3-2 and Figure 3-8). With knowledge of their TBI
app

behavior the steady state, 𝐾𝐾i

values were then pursued using the Morrison analysis (Eq. 3.1),

and with knowledge of their slow onset mechanism of inhibition, the kinetic koff and tR
parameters for each of the inhibitors could then be derived from analysis of progress curves as
app

described above.106, 107 Because Ki is equal to the ration of koff / kon, the 𝑘𝑘on can then be derived
app

from the calculated 𝐾𝐾i

and koff values. The tR was derived independently for each progress

curve and averaged to generate values similar to, but independently calculated from, the koff
values. The results of this analysis are summarized in Table 3-2.
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Figure 3-8. Preliminary dose-response experiments demonstrating inhibition of H10MbtAopt.
The data shown for each inhibitor (indicated in the label of the x axis) is derived from one of two
independent dose-response experiments using H10MbtAopt at 250 nM. The IC50 values were
calculated by fitting the dose-response datasets (•) to the sigmoidal equation
vi⁄v0 = b + a - b⁄1 + ( [I]⁄IC50 )s, where vi and v0 are initial reaction velocities of inhibitorcontaining reactions and DMSO-containing reaction controls (no inhibitor), respectively, a and b
are the top and bottom of the sigmoidal curve (solid line; R2 values ≥ 0.988), respectively, and s
is the Hill coefficient. Adapted from [74].
app

Our analysis of the inhibitor set calculated 𝐾𝐾i

values in ranging from 27–295 nM (≈11-

fold relative spread) and indicates that all the inhibitors have relatively similar and potent activity
app

against H10MbtAopt. As expected, the 𝐾𝐾i

values had a better discrimination power of inhibitory

activity than the IC50 calculations which ranged only from 117–289 nM (≈2.5-fold relative
app

spread).88 The calculations of 𝑘𝑘on ranged from 0.00004–0.00066 nM-1min-1 (≈17-fold relative

spread), whereas the koff values and the tR values ranged from 0.007–0.031 min-1 and
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Table 3-2. Kinetic parameters for inhibitors of MbtAtb. Adapted from [74].
app

-1
-1
kapp
on (nM min )

koff (min-1)

tR (min)

26.6 ± 2.5

0.00027 ± 0.00003

0.007 ± 0.001

157 ± 22

153.6 ± 2.5∗b

62.1 ± 5.0∗∗∗

0.00016 ± 0.00002∗

0.010 ± 0.001

109 ± 13

3a

150.9 ± 7.8

26.6 ± 6.4

0.00066 ± 0.00012∗

0.019 ± 0.005∗

76 ± 24∗

3b

226.0 ± 3.0∗∗∗

89.0 ± 15.4∗∗

0.00030 ± 0.00006

0.031 ± 0.009∗

60 ± 26∗

4a

245.6 ± 2.9∗∗∗

295.3 ± 23.9∗∗∗

0.00007 ± 0.000002∗∗∗

0.020 ± 0.002∗∗∗

54 ± 7∗∗

4b

174.6 ± 4.3∗∗

158.5 ± 8.1∗∗∗

0.00006 ± 0.00001∗∗∗

0.009 ± 0.001

5a

185.0 ± 1.6∗∗∗

125.6 ± 6.2∗∗∗

0.00011 ± 0.00001∗∗∗

0.013 ± 0.001∗∗

79 ± 8∗∗

5b

192.1 ± 6.4∗∗

148.7 ± 9.8∗∗∗

0.00010 ± 0.00002∗∗

0.015 ± 0.003∗

82 ± 22∗

6

288.9 ± 16.4∗∗

277.1 ± 12.2∗∗∗

0.00004 ± 0.00001∗∗∗

0.012 ± 0.002∗

87 ± 12∗

Cmpd.

IC50 (nM)a

Ki

1

117.2 ± 0.3

2

(nM)

121 ± 22

a

, Values represent means ± SEM derived from two independent experiments for IC50 values
(Figure 3-8) and at least 5 for other parameters. b, Statistical significance as per Student’s t-test is
indicated. ∗, ∗∗, and ∗∗∗ represent p values of ≤ 0.05; ≤ 0.01, and ≤ 0.001, respectively, for
analogues vs. 1. •, ••, and ••• represent p values of ≤ 0.05; ≤ 0.01, and ≤ 0.001, respectively, for
3a vs. 3b, 4a vs. 4b, and 5a vs. 5b pairs. No dots or asterisks indicate no statistical significance.
54–157 min, respectively (4-fold and 3-fold relative spread, respectively). The members of this
inhibitor set are relatively similar in terms of their overall kinetic parameters, with none of the
structural modifications setting them apart from salicyl-AMS (1) dramatically, a finding
encouraging their progression to downstream studies of their clinical worth. Pearson pairwise
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statistical correlation analysis demonstrated relatively strong correlations between IC50 and 𝐾𝐾i
values, as can be expected due to their shared analysis of steady-state binding [Pearson

correlation coefficient (PCC) = 0.86, p value = 0.003] and between koff and tR values (PCC = 0.79, p value = 0.012) which are mathematically related. The correlation analysis also showed a
app

weaker but statistically significant correlation between 𝐾𝐾i

app

and 𝑘𝑘on values (PCC = -0.69, p

value = 0.040), perhaps signifying the disproportional effect of kon on the steady-state apparent
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inhibition constants of these inhibitors and arguing to focus more on the pharmacologically
significant koff instead.

Figure 3-9. Two-dimensional kinetic map for salicyl-AMS and its analogues.
The map represents the data summarized in Table 3-2 and facilitates visualization of
app
app
relationships between inhibitors and the kinetic parameters koff, 𝑘𝑘on , tR, and Ki (diagonal
dashed lines) noted in the text. The clustering of analogues with sulfamide-based linkers (4a, 4b,
6; red oval), modifications at C2 (3a, 3b; green oval), and modifications at C6 (5a, 5b, 6; blue
oval) is indicated. Adapted from [74].
A two-dimensional kinetic map representation of the kinetic parameters illustrated
several SAR trends and inhibitor clustering patterns that correlate to the types of modifications
made to the lead compound salicyl-AMS (Figure 3-9). This map can be made because of the
relationship between these parameters of inhibition (Ki = koff / kon and tR = 1 / koff). Ultimately,
app

the Ki

of salicyl-AMS (1) (27 nM) was the lowest in the inhibitor set and demonstrated the best

tR (157 min). Considering that salicyl-AMS (1) has the most similar structure in the series to that
of the natural salicyl-AMP reaction intermediate, this is perhaps not surprising.
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The loss of the ribose 2´-hydroxyl in salicyl-2´-dAMS (2) was well tolerated among the
calculated parameters relative to salicyl-AMS (1), only modestly negatively affecting any value
(≤2-fold change). This is demonstrated by its close proximity to salicyl-AMS (1) on the kinetic
map (Figure 3-9). Previously, Aldrich reported salicyl-2´-dAMS (2) to exhibit only a 2-fold
increase in potency relative to salicyl-AMS (1) (as per the ATP-PPi assay).65
Clustering on the map was seen for all analogues with C6-substituent adenine ring
modifications (5a, 5b, 6) with respect to tR and koff, showing a ≈2-fold reduction compared with
salicyl-AMS (1) (Figure 3-9). The pair with the sulfamate-based linker matching the salicylAMS lead compound with 6-amino substituents (5a, 5b) were essentially indistinguishable from
app

each other with respect to 𝐾𝐾i

app

and 𝑘𝑘on values. As compared to salicyl-AMS (1), both 5a and 5b

exhibited a ≈5.5-fold worsening of 𝐾𝐾i

app

and ≈2.5-fold worsening of 𝑘𝑘on . In contrast, the 6app

app

methoxy group in the novel salicyl-6-MeO-AMSN (6) led to a more dramatic worsening of 𝐾𝐾i

and 𝑘𝑘on , with ≈10-fold and ≈6-fold changes compared to salicyl-AMS (1), respectively.
app

It should be noted that the worsening of analogue 6 may be the result of a simultaneous

negative effect from the additional replacement of the sulfamate linker with a sulfamide linker.
Indeed, the sulfamide linker replacements in analogues 4a, 4b, and 6 correlated with the worst
app

𝐾𝐾i

app

and 𝑘𝑘on values in the series, as seen by their placement towards the top left of the kinetic

map (Figure 3-9). This negative impact contrasts with an initial SAR study reporting essentially
app

indistinguishable 𝐾𝐾i

values for 4a and salicyl-AMS (1) as determined using the ATP-PPi

assay.73 This difference may be due to the different experimental conditions used in the studies
(i.e.: different assay, recombinant proteins, batches of inhibitors, etc.). Notably, the addition of
the 5´-N-methyl substituent the novel salicyl-AMSNMe (4b) led to a modest 2-fold improvement
app

in the 𝐾𝐾i

compared to 4a. This suggests that alterations to the sulfamide linker might be a
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strategy to alleviate negative effects of this linker on potency while maintaining its enhanced
stability compared to the sulfamate linker in salicyl-AMS (1).
The final two analogues with aryl substituents at the adenine C2 position (3a, 3b)
clustered away from the rest of the inhibitor set and displayed the worst koff and tR values in the
app

series. Although these analogues exhibited only modest (3b) or no (3a) worsening as per 𝐾𝐾i
app

compared to salicyl-AMS (1), this was due specifically to an increase in 𝑘𝑘on values which was

compensated for by the concurrent worsening of koff. Fast koff rates are typically viewed as an
app

undesired property103, 118 and traditional analysis of steady-state parameters (𝐾𝐾i

& IC50) would

not reveal that these inhibitors may be less effective in vivo. It is tempting to speculate that the
bulky additions in analogues 3a and 3b compromise some of the binding interactions in the
MbtAtb active site, perhaps facilitating dissociation and reducing the lifetime of the enzymeinhibitor complexes.
Contrasting with our results, a previous study reported analogues 3a, 3b, 5a, and 5b to be
≈4–24-fold more potent than salicyl-AMS (1) as per 𝐾𝐾i

app

app

assay.71 It appears that this study referenced a 𝐾𝐾i

values determined using the ATP-PPi

value for salicyl-AMS (1) that was

determined separately in an initial study along with analogue 2 and 4a,71 perhaps explaining the
overall discrepancy with the findings reported herein. Kinetic parameters are highly dependent
on experimental conditions, so we believe that our simultaneous comparison, in which each of
independent experimental replicates included every inhibitor tested with the same buffer
app

preparations, is likely to offer a more reliable comparison of the set’s 𝐾𝐾i

values.

Interestingly, salicyl-6-MeO-AMSN (6) is a fairly potent inhibitor of MbtAtb despite the

lack of a hydrogen-bond donor on the C6-substituent and the presence of the sulfamide linker.
This result was unexpected based on conclusions drawn from previous SAR studies,71 and is not
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readily rationalized based on protein structure analysis.112, 115 Nonetheless, it opens the door to
further investigation of such C6-substituents, perhaps being careful to maintain the protonation
state of the neighboring nitrogen and not to introduce steric constraints (as per inhibitors 11 and
12; Figure 3-3B).

Conclusions
We successfully calculated the previously unmeasured intrinsic inhibition of MbtA by
salicyl-AMS. These values are essentially indistinguishable from one another, demonstrating
correspondence between the two evaluation approaches with respect to substrate and
emphasizing the robustness of the methodological approach. The calculated Ki value (≈1 nm) is
consistent with the inhibition of YbtE and EntE by Salicyl-AMS. We tested two novel analogues
of salicyl-AMS alongside six of the strongest previously assessed analogues. Our analyses
indicate that they all are potent and competitive TBIs with a static, slow-onset mechanism of
inhibition.
As per our kinetic analysis, the inhibitors are relatively similar to one another, with a
considerable tR. The new salicyl-6-MeO-AMSN (6) analogue is a fairly potent MbtAtb inhibitor,
a property unexpected based on previously published SAR analysis and modeling studies.
Previous SAR determined that loss of the C6-substituent hydrogen-bond donor with V352 results
in loss of activity, but MbtA inhibition by 6 demonstrates this may have been due to
conformational changes of 11 and steric clash of 12 with V352. These findings further warrant
the exploration of C6-substituent analogues. Additionally, the second new analogue salicylAMSNMe (4b) has improved MbtAtb inhibitory potency compared with the unsubstituted
counterpart. This analogue was designed to promote a favorable pharmacophoric cisoid
conformation and highlights these substitutions as deserving further investigation.
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CHAPTER 4: ANTIMYCOBACTERIAL ACTIVITY OF THE
SIDEROPHORE BIOSYNTHESIS INHIBITOR SALICYL-AMS AND
ANALOGUES
Introduction
The inhibitory efficacy of salicyl-AMS and its structural analogues against the MbtA
adenylation enzyme target has been exhaustingly demonstrated, previously and herein (Chapter
3).64, 66 In addition, ability of salicyl-AMS to successfully inhibit growth of Mtb was initially
established by the Quadri and Tan labs.64, 66 This was independently verified for salicyl-AMS
and some of its analogues by Aldrich and coworkers.66 Salicyl-AMS has been proven to both
diminish production of MBTS as well as display antimicrobial activity against Mtb in an iron
concentration-dependent fashion.64, 66 This reliance on low iron concentrations for growth
inhibition agrees with the antibiotic’s mode of action. Of course, due to the sequestering of iron
by the host during infection, low iron conditions emulate the in vivo environment of Mtb during
infection of the macrophage.119 The MIC of salicyl-AMS against Mtb under iron-limiting
conditions has been shown to be within the range of 0.1 – 0.5 µg/ml.31, 71, 72 Interestingly, in ironrich conditions, salicyl-AMS has demonstrated only a 4-fold71 to 20-fold64 decrease in activity.
This observation has been attributed to either off-target effects of the compound or a reliance of
Mtb on MBTS for iron acquisition in iron-rich environments.71
In addition to the MIC, information on the postantibiotic effect (PAE) is an important
consideration to the lead optimization and prioritization phases of antibiotic development.120-122
PAE is a pharmacodynamic characteristic regarding the delayed regrowth of surviving bacteria
following short term exposure to an antimicrobial.120 PAE was described initially in 1944 using
the response of organisms to penicillin, but was recognized for its clinical significance in the
1970s.120 The cause of this phenomenon is thought to stem from an antibiotic’s effects on
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enzyme activity, cell morphology, metabolism, generation time, receptor presentation, and other
factors.122 By the mid-1990s, PAE was being applied increasingly to the design of dosing
regimens as a way to better determine the proper scientific basis for frequency of antibiotic
administration.122 Interestingly, TB antibiotics such as isoniazid and rifampicin were found to
suppress growth for periods of up to 48 hours after drug tissue concentrations fell below
inhibitory concentrations.122 With this knowledge, drug administrations were modified for TB
patients, marking one of the first clinical applications of pharmacodynamics for clinical
purposes.122 Recently, the PAEs for inhibitors of the Pseudomonas aeruginosa LpxC enzyme
were found to strongly correlate with the compounds’ in vitro tR values, which relates to how
long an inhibitor remains in complex with its enzyme target.123 It has also been argued that tR is a
stronger measure of an inhibitor’s in vivo efficacy than traditional inhibition constant
app

measurements (e.g. IC50, Ki, Ki ).100 It is tempting to speculate that the observed correlation
between residence time and PAE are due to the maintenance of drug at the enzyme active site
after the short drug exposure. Pharmacodynamics as a whole has implications for a drug’s
efficacy, toxicity, cost, and compliance.122 Despite this, PAE studies have not been undertaken
previously for salicyl-AMS or any of its analogues.
Due to the extremely long doubling time of Mtb (≈24 hours) and its requirement for
Biological Safety Level 3 (BSL-3) handling, screening inhibitors for whole-cell growth
inhibition with this species is difficult and the slow growth has made PAE studies highly difficult
to pursue. In contrast, M. smegmatis (Msm) is a rapidly growing (≈3 hour doubling) and
nonpathogenic NTM often used as a surrogate for Mtb. Msm contains a highly homologous
MBTS biosynthesis pathway,34 an MbtA orthologue (MbtAsm) with 71% amino acid identity to
the that of Mtb MbtA, and MBTS structurally identical to those of Mtb besides a minor
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stereochemistry change of a methyl group and the range of the variable lipid moiety length at
position R5 (Figure 1-6).27 Despite this, Msm has not been used as a model to measure salicylAMS antimicrobial activity due to a redundant EXO siderophore system, accounting for 90-95%
of the organism’s siderophore activity (Figure 1-5).124, 125 This leaves opportunity for the
construction of a Msm strain deficient in EXO production that can be used to screen inhibitors
disrupting the MBTS biosynthesis pathway. In addition, use of a ∆mbtA Msm strain34 would
allow for introduction of the heterologous MbtA from Mtb (MbtAtb) for production of the
MTBS. This EXO deficient strain producing MBTS reliant on MbtAtb would be an efficient
model strain for the assessment of salicyl-AMS analogues’ antimicrobial activity against the
clinically relevant protein target.
We report herein detailed in vitro evaluation of salicyl-AMS, two novel salicyl-AMS
analogues designed to probe new SAR alterations, and six of the most potent analogues reported
previously by Aldrich and coworkers.66 We developed a new cellular model using the nonpathogenic, fast-growing Msm species allowing for better throughput screening of Mtb MbtA
inhibitors. We then applied this model to evaluate the inhibitor collection for MIC values and
PAE effects in cell culture.

Materials and Methods
Bacterial culturing and recombinant DNA manipulations. Msm mc2155 (ATCC
700084)126 and its derivatives were regularly cultured under standard conditions in Middlebrook
7H9 or 7H11 (Difco) supplemented as reported.34 Msm strains were cultured in Fe-limiting
GASTD medium or GASTD supplemented with 100 µM FeCl3 (GASTD+Fe medium)56, 64 for
specific experiments as noted below. Routine culturing of E. coli strains was done under standard
conditions in Luria-Bertani media.83 When required, kanamycin (30 μg/ml), chloramphenicol
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(34 μg/ml), ampicillin (100 μg/ml), sucrose (2%), and/or 5-bromo-4-chloro-3-indolyl-β-dgalactopyranoside (X-gal, 70 μg/ml) were added to the growth media. DNA manipulations were
carried out using established protocols and E. coli DH5α as the primary cloning host.83 PCRgenerated DNA fragments used in plasmid constructions were sequenced to verify fidelity. The
oligonucleotides used in this study are shown in Table S3. Genomic DNA isolation, plasmid
electroporation into Msm, and selection of Msm transformants were carried out as reported.34
Unless otherwise indicated, molecular biology, biochemical, and microbiology reagents were
purchased from Sigma-Aldrich Inc., Thermo Fisher Scientific Inc., New England Biolabs Inc.,
QIAGEN Inc., or Integrated DNA Technologies Inc.
Generation of M. smegmatis mutants ΔE, ΔEM, and ΔEM-pMbtAtb. Mutants were
generated using the p2NIL/pGOAL19-based flexible cassette method,127 as reported.34 Msm ΔE
carried an unmarked, in-frame deletion of MSMEG_0019, encoding the peptide synthetase
(7,523 amino acids, the largest protein in Msm128) predicted to be essential for biosynthesis of
exochelin (EXO) siderophores.129-131 A MSMEG_0019 deletion cassette-delivery, suicide
plasmid (pΔ0019) was used to generate the chromosomal deletion, which eliminated codons 5
through 7,519 of the gene. The deletion cassette contained from 5´- to 3´-end: the 984-bp
segment upstream of the gene, the gene’s first 4 codons, the gene’s last 4 codons, the stop codon,
and the 1,029-bp segment downstream of the gene. To generate the cassette, primer pair OF0019
and IR0019soe and primer pair IF0019soe and OR0019 were first used to generate the 5’
fragment (1,011 bp) and the 3’ fragment (1,059 bp) for the cassette, respectively, from genomic
DNA template. The fragments, which had a 30-bp overlap at the splice site embedded in
IF0019soe and IR0019soe, were then used together as a template for PCR with primers OF0019
and OR0019 to fuse the fragments. The PCR-generated cassette was cloned into pCR2.1Topo
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(TOPO TA Cloning Kit, Invitrogen, Thermo Fisher Scientific Inc.), then excised from the
pCR2.1Topo construct using HindIII and EcoRV, and religated into p2NIL127 linearized by
HindIII-PmlI digestion. The resulting plasmid (p2NILΔ0019) and pGOAL19127 were digested
with PacI, and then the PacI marker cassette of pGOAL19 was ligated to the linearized
p2NILΔ0019 to create pΔ0019. Electroporation of pΔ0019 into Msm wild-type (WT) and
selection of potential single- and double-crossover mutants were conducted as reported.34 The
MSMEG_0019 deletion was screened for and confirmed by PCR using two primer pairs
(OF0019 and OR0019: yielding an undetectable 24,585-bp amplicon for WT and a 2,040-bp
amplicon for mutant; IF0019 and IR0019: yielding a 148-bp amplicon for WT and no amplicon
for mutant) (not shown).
EXO/MBT-deficient Msm ΔEM carried the MSMEG_0019 deletion noted above and an
unmarked, in-frame deletion of M. smegmatis mbtA (mbtAsm), which encodes the salicylate
adenylation enzyme essential for MBT biosynthesis.34 The mbtAsm deletion left behind only the
gene’s start codon followed by the stop codon, and it was created in Msm ΔE with the same
approach we have previously reported for generation of the identical mbtAsm deletion in Msm
WT to generate the mutant referred to hereafter as Msm ΔM.34
Msm ΔEM was transformed with plasmid pMbtAtb (expressing mbtAtb) to generate strain
Msm ΔEM-pMbtAtb. To construct pMbtAtb, a DNA fragment encompassing mbtA of Mtb
(mbtAtb, Rv238434) was generated by PCR from genomic DNA template using primer pair
mbtAtbF1 and mbtAtbR1. The PCR product, which included an optimized ribosome-binding
site132 upstream of mbtAtb introduced by primer mbtAtbF1, was cloned into pCR2.1Topo.
Subsequently, the insert was recovered from the pCR2.1Topo construct as a HpaI-NheI fragment
and subcloned into the mycobacterial, low-copy number plasmid pCP0133 linearized by HpaI-
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NheI digestion. This subcloning created pMbtAtb, in which mbtAtb is under the control of the
constitutive mycobacterial hsp60 promoter located in pCP0.
Evaluation of mycobactin production by radio-thin layer chromatography.
Production of MBT and its inhibition by 1 (200 µM) was evaluated by radio-thin layer
chromatography (TLC) analysis of 14C-labeled MBTs obtained by feeding the cultures the MBTspecific [14C]salicylate radiotracer, as performed previously.34, 64
Growth inhibition assays. Dose-response experiments using microdilution assays in a
96-well plate platform were performed as reported.56, 57 Msm strains were grown in GASTD or
GASTD+Fe media. Cultures (200 µL/well) were started at OD600 = 0.0005 (≈9×104 CFU/well, as
per concurrent CFU determination) from culture stocks prepared in GASTD medium as
reported.64 Growth was assessed as OD600 after 4 days of incubation (37 °C, 170 rpm) using the
DTX 880 microplate reader. Unless otherwise indicated in specific experiments, compounds
were evaluated using a 2-fold dilution series format starting at 64 µg/ml for inhibitors 1 and 6, 62
µg/ml for inhibitors 3a and 3b, and 61 µg/ml for inhibitors 2, 4a, 4b, 5a, and 5b. Inhibitors were
added from 10% DMSO stock solutions, with a final DMSO concentration of 0.5% in both
inhibitor-treated cultures and DMSO controls (no inhibitor). Minimum inhibitory concentration
(MIC) values were calculated as the lowest concentration tested that inhibited growth by ≥95%
relative to DMSO controls. Data presented are derived from three independent experiments.
Post-antibiotic effect (PAE) assays. Cells from mid-log growth phase cultures of Msm
∆EM-pMbtAtb in GASTD medium (37 °C, 170 rpm, OD600 ≈ 0.75) were harvested by
centrifugation and washed in GASTD medium (3 times with 1 culture volume). The washed cells
were resuspended in GASTD medium and transferred to U-bottom 96-well cell culture plates
(Corning, Inc.) for inhibitor exposure at a cell density corresponding to OD600 = 1.0 (50
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µL/well). Cells were exposed to 5×, 50×, and 100× average MIC value, in line with reported
studies with other antimycobacterial compounds.134 Inhibitors were added from 10% DMSO
stock solutions, with a final DMSO concentration of 1% in both inhibitor-exposed cultures and
DMSO controls (no inhibitor). After the exposure period (1 h, 37 °C, 170 rpm), the cultures were
diluted in pre-warmed, inhibitor-free medium to OD600 = 0.001 (1,000-fold dilution, bringing
inhibitor concentrations to 0.005×, 0.05×, and 0.1× average MIC values) and reseeded into flatbottom, 96-well culture plates (Corning, Inc.) at 200 µl/well. The 96-well plates were incubated
for culture growth at 37 °C in a FLUOstar Optima microplate reader (BMG Labtech, Inc.), and
OD600 readings were taken every 30 min following plate shaking (5 min, 200 rpm) for 5 days.
The growth vs. time datasets were analyzed to determine the time at which cultures reached an
exponential growth phase threshold of OD600 = 0.05 (≈15% of maximal growth). The time-tothreshold data were used to calculate PAE as the difference between the time-to-threshold values
of the inhibitor-exposed culture and the control cultures.135 Data presented are derived from
three independent experiments. Pearson correlation analysis between PAE and tR datasets was
carried out using Prism v6.01, and PCCs with p values ≤0.05 were considered statistically
significant.

Results and Discussion
Construction of a M. smegmatis strain with MbtAtb-dependent susceptibility to
salicyl-AMS. Using Mtb to study the antimicrobial properties of lead compounds is challenging
due to the need for BSL-3 procedures and the bacterium’s slow growth rate. We sought to use
the nonpathogenic, fast-replicating Msm model system to strengthen the methodological
approach to study MbtAtb inhibitors’ antimicrobial properties. As discussed, Msm has closely
related MBTS to Mtb, and the Quadri lab has previously shown that the MbtAtb orthologue in
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Msm (MbtAsm) (71% sequence identity) is essential for their biosynthesis.34 However, the
secondary EXO siderophore system, accounting for 90-95% of siderophore activity, could
confound its use as a model system.124, 125 We hypothesized that production of EXO would
confer salicyl-AMS (1) resistance to Msm, impeding its use for evaluation of MbtA inhibitors.
To generate an effective Msm model for evaluation of MbtA inhibitors, a mutant deficient in a
NRPS necessary for EXO biosynthesis was generated and deemed Msm ∆E. When
characterizing the strain, a previously generated Msm MBTS deficient strain lacking mbtA was
included, herein referred to as Msm ∆M.34
We first evaluated the capacity of Msm WT, Msm ∆E, and Msm ∆M to produce the two
unrelated classes of siderophores. Production of EXO was assessed using the CAS-Q
siderophore assay. Msm EXO are responsible for the siderophore positive phenotype on the
CAS/CAS-Q agar plate-based siderophore detection assay while mycobactin production does not
cause the change, perhaps due to the overwhelming activity of EXO in Msm.124, 125, 129-131 CAS
agar changes color from blue-green to yellow upon removal of ferric iron from the chrome
azurol S/ODTMABr complex.136
The CAS-Q agar assay is a variation of the traditional CAS agar136 containing
octadecyltrimethylammonium bromide (ODTMABr) versus the hexadecyltrimethylammonium
bromide (HDTMABr) which has growth inhibitory activity against various fungi and grampositive bacteria, including mycobacteria.129, 136-140 After evaluation of various substitutes for
HDTMABr, the Quadri lab found that the ODTMABr-based CAS-Q agar is better tolerated by
mycobacteria and permits more robust and reliable bacterial growth than CAS agar (not shown).
The CAS-Q assay revealed that strains with an in-tact EXO biosynthetic pathway generated the
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expected yellow coloration, while those with a knock-out of the NRPS responsible for EXO
biosynthesis did not cause the change (Figure 4-1A).
The production of MBT in the recombinant Msm strains was then evaluated by radio-thin
layer chromatography (TLC) analysis of 14C-labeled MBTS, obtained by feeding the cultures the
[14C]salicylate radiotracer MBTS precursor.34, 64 Radio-labeled salicylic acid is incorporated into
the structure of MBTS in the first step of siderophore biosynthesis, allowing for visualization of
the end product after chloroform extraction of cell associated MBT and separation by TLC. The
analysis demonstrated that only those strains with an intact mbtA produced MBT, while mbtA
mutants were defective in its biosynthesis (Figure 4-1B).

Figure 4-1. Siderophore production in the constructed Msm strains.
(A) Evaluation of exochelin production using the CAS-Q siderophore assay. Exochelin
production is responsible for the change of the CAS-Q agar color from blue-green to yelloworange upon the removal of the ferric iron from the chrome azurol S/ODTMABr complex (Msm
patches 1 and 3). Msm strains were patched and the plate was imaged after 5 days of incubation
at 37°C. Strains: 1, WT; 2, ∆E; 3, ∆M; 4, ∆EM, 5, ∆EM-pMbtAsm; and 6, ∆EM-pMbtAtb. (B)
Radio-thin layer chromatography (TLC) analysis of 14C-labeled MBTs. Lanes: 1, WT; 2, ∆M; 3,
∆E; 4, ∆EM, 5, ∆EM-pMbtAsm; 6, ∆EM-pMbtAtb; 7, ∆EM-pMbtAtb with DMSO treatment
(control); 8, ∆EM-pMbtAtb with inhibitor 1 treatment. The Msm ∆M strain represents a no MBT
production control.34 The image shows the entire TLC plate. The results are representative of
two independent experiments. The solvent system is indicated. Ori, origin; SF, solvent front.
Adapted from [74].
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We then investigated the susceptibility of Msm WT, Msm ∆E and Msm ∆M to salicylAMS (1) in iron-limiting and iron-rich growth media (Table 4-1; Figure 4-2B). As expected,
only Msm ∆E was susceptible to salicyl-AMS (1) with an MIC of 0.5–1 µg/l. The antimicrobial
activity of salicyl-AMS (1) was conditional on the iron-limiting condition, consistent with its
mechanism of inhibiting biosynthesis of MBTS. With minimal iron present in the medium, Msm
∆E relied on MBTS to acquire the iron needed for growth.
Table 4-1. Susceptibility of M. smegmatis strains to salicyl-AMS. Adapted from [74].
MIC (µg/ml)b

Msm strain
(EXO / MBT)a

GASTD
medium

GASTD+Fe
medium

Msm WT
(+ / +)

>1000

>1000

Msm ΔE
(- / +)

0.5 – 1.0

>1000

Msm ΔM
(+ / -)

>1000

>1000

Msm ΔEM
(- / -)

no growth

>1000

Msm ΔEM-pMbtAtb
(- / +)

0.5 – 1.0

>1000

a

, The siderophore production phenotype of each strain is indicated between brackets. EXO,
exochelins; MBT, mycobactins; +, production; -, deficiency. b, MIC data shown is derived from
three independent experiments.
An additional “double-mutant” lacking both mbtA for MBTS production and the NRPS
for EXO production (siderophore deficient Msm; Figure 4-1), deemed Msm ∆EM, failed to grow
in the iron-limiting medium (Table 4-1; Figure 4-2A). Interestingly, this lack-of-growth
phenotype in the control strain can be viewed as a reference for the effect of effectively
inhibiting MbtA 100% in Msm ∆E. When mbtAsm was reintroduced episomally into the Msm
∆EM strain, the lack-of-growth phenotype was strongly complemented (Figure 4-2A), ruling out
the possibility that the phenotype resulted from confounding mutations or polar effects in the
double-mutant. The lack of growth of the siderophore-deficient Msm ∆EM mutant in the iron80

limiting medium and correction of the growth defect by addition of iron to the culture medium
(Figure 4-2A) is in agreement with previous observations.47, 53 Additionally, the growth defect
mimics the phenotype seen for Mtb mutants deficient in MBTS.23, 28, 52-55

Figure 4-2. Phenotypes and salicyl-AMS susceptibility of the Msm strains.
(A) Representative growth curves of the indicated Msm strains in GASTD (left plot) and
GASTD+Fe (right plot) media. (B) Representative dose response curves showing susceptibility
of Msm ∆E (left plot) and Msm ∆EM-pMbtAtb (right plot) to salicyl-AMS (1) in GASTD
medium. Adapted from [74].
Notably, the lack of salicyl-AMS (1) susceptibility of strains producing EXO under the
iron-limiting conditions and of all strains under in iron-rich conditions indicated that there is no
significant off-target effects in Msm (Table 4-1). This finding contrasts with the observation that
salicyl-AMS (1) (Table 4-1) and analogues 3a, 3b, 5a, and 5b (Table 4-2) have significant
antimycobacterial activity against Mtb, even in iron-rich media (4–64 fold MIC increase in iron81

limiting conditions).71 Previously, this observation in Mtb was attributed to off-target effects, and
analogue 5b was considered an attractive lead compound due to its larger 64-fold relative
change, indicating better specificity to MbtAtb.71 Interestingly, as discussed above, our review of
the literature revealed that different MBTS-deficient mutants have displayed either a significant
growth defect23, 52-54, 60 or no defect28, 55 compared with WT in iron-rich conditions. This
difference is study-dependent and suggests that either MBTS are needed for WT growth in ironrich conditions, or that the phenotype is sensitive to unknown experimental conditions.
Accordingly, it is difficult to determine whether MbtAtb inhibitors’ antimicrobial activity is due
to inhibition of MBTS biosynthesis, off-target effects, or a combination of both. Thus, the
possibility of off-target effect confounders in Mtb-based SAR analyses of MbtA inhibitors
cannot be ruled out, a disadvantage not found with the Msm model developed herein, and may
lend more knowledge towards on-target activity.
Our results demonstrated a potent and selective antimicrobial activity of salicyl-AMS (1)
against Msm ∆E. We then explored the development of a Msm EXO deficient strain that is
dependent upon MbtAtb for production of MBTS, which is the clinically relevant target of
salicyl-AMS (1). To achieve this, the Msm ∆EM double-mutant was transformed with the
pMbtAtb vector to heterologously express mbtAtb. We found that the heterologusly
complemented strain (Msm ∆EM-pMbtAtb) regained ability to produce MBT as per radio-TLC
analysis (Figure 4-1). Additionally, the new strain was similar to Msm ∆E in terms of
susceptibility to salicyl-AMS (1) in high and low-iron conditions (Table 4-1 and Figure 4-2B).
Moreover, 200 µM of salicyl-AMS (1) inhibited MBT production in Msm ∆EM-pMbtAtb as per
radio-TLC analysis (Figure 4-1), a result paralleling that seen with Mtb when the inhibitor was
initially characterized by the Quadri lab.64 Taken together, these results established that Msm
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∆EM-pMbtAtb has high, MbtAtb-dependent salicyl-AMS susceptibility, and is a convenient
model system to assess and compare the antimycobacterial properties of the MbtAtb inhibitors.
Antimicrobial activity of salicyl-AMS and analogues. With the new analogues of
interest (4b & 6), we aimed to evaluate their antimicrobial activities using the Msm ∆EMpMbtAtb model system alongside lead compound salicyl-AMS (1) and the six previously
reported analogues (2, 3a, 3b, 4a, 5a, & 5b). We determined MIC values and investigated in
vitro PAE using for the inhibitor set simultaneously (Table 4-2). Despite the relevance of PAE
information to the lead optimization and prioritization phases of antibiotic development,120-122
this is this first study investigating PAE for any of these inhibitors.
Evaluation of antimicrobial activity in iron-limiting media revealed MIC values ranging
from 0.8–5.3 µg/mL (≈6-fold relative spread), indicating a shared potent activity amongst the
app

MbtAtb inhibitor set. This narrow range parallels the modest, 11-fold relative Ki

range (Table

3-2). Salicyl-AMS (1) (0.8 µg/mL) was among the most potent of inhibitors (Table 4-2),
mirroring the results of the kinetic parameters measured in Chapter 3 (Table 3-2). Pearson
correlation analysis revealed no significant correlation between the antimicrobial potency and
MbtAtb inhibitory potency informed by kinetic parameters (PCC < 0.5). The relatively small
differences seen in in vitro potency are probably overpowered by the numerous cellular factors
known to impact its translation into cell-based assay potency (e.g., drug
penetration/efflux/inactivation, non-specific off-target binding, target vulnerability/turnover,
etc.),121, 141 and it is likely that any existing correlation of in vitro results with whole-cell activity
would have been confounded. Of course, koff has been considered a desirable characteristic for
translating in vitro potency to downstream evaluations, but this is more indicative of efficacy in
the animal model where pharmacokinetic properties are taken into account.103
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Table 4-2. Antimicrobial activity and post-antibiotic effect of MbtAtb inhibitors in M.
smegmatis ∆EM-pMbtAtb. Adapted from [74].
MIC (µg/ml)a
Cmpd.

GASTD medium

PAE (hours)c

range

mean

GASTD+Fe
medium

1

0.5 – 1.0b

0.8 ± 0.2

>64

9.4 ± 1.6

14.2 ± 0.9

34.5 ± 1.8

2

4.0 – 8.0

5.3 ± 1.3∗d

>64

-0.1 ± 0.8∗∗

12.3 ± 3.5

32.7 ± 2.5

3a

1.0 – 2.0

1.3 ± 0.3

>64

5.7 ± 2.9

30.3 ± 5.5∗

49.9 ± 3.7∗

3b

1.0

1.0 ± 0.0

>64

14.4 ± 1.9

25.0 ± 1.0∗∗

35.7 ± 2.0

4a

1.0

1.0 ± 0.0

>64

10.6 ± 2.7

18.7 ± 1.3

23.1 ± 3.1∗

4b

0.5 – 1.0

0.8 ± 0.2

>64

13.4 ± 2.6

17.4 ± 4.7

19.4 ± 2.2∗∗

5a

2.0 – 4.0

2.7 ± 0.7

>64

9.0 ± 0.9

12.2 ± 1.2

32.9 ± 6.2

5b

4.0 – 8.0

5.3 ± 1.3∗

>64

4.0 ± 1.5

23.2 ± 2.9∗

45.7 ± 3.8

6

4.0 – 8.0

5.3 ± 1.3∗

>64

18.6 ± 2.8∗

ND

ND

5× MIC

50× MIC

100× MIC

, MIC data against Msm ∆EM-pMbtAtb shown represent ranges and mean values ± SEM of n = 3
independent experiments. b, The MIC value for 1 was derived from experiments independent from
those that rendered the MIC value shown in Table 4-1. c, PAE was calculated as the difference
between the time-to-threshold values of the inhibitor-exposed culture and the control cultures
(Figure 4-3). The PAE data in Msm ∆EM-pMbtAtb represent mean values ± SEM of n = 3
independent experiments. d, Statistical significance as per Student’s t-test is indicated. ∗, ∗∗, and
∗∗∗ represent p values of ≤ 0.05; ≤ 0.01, and ≤ 0.001, respectively, for analogues vs. 1. • represents
p value of ≤ 0.05 for 3a vs. 3b, 4a vs. 4b, and 5a vs. 5b pairs. No dots or asterisks indicate no
statistical significance. ND, not determined.
a

Encouragingly, the novel salicyl-AMSNMe (4b) and salicyl-6-MeO-AMSN (6)
analogues were potent antimicrobials against the Msm model system. While analogue 4b, with a
N-methylsulfamide linker, had an MIC value indistinguishable from that of salicyl-AMS (1), the
6-methoxy analogue 6 displayed one of the largest ≈6-fold worsenings in potency compared to 1.
There were no statistically significant differences between the MIC values of 1 with the
previously reported 3a, 3b, 4a, and 5a. The salicyl-2´-dAMS (2) and salicyl-6-N-c-Pr-AMS (5b)
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analogues showed a significant ≈6-fold decrease in potency compared to 1 (Table 4-2). Notably,
no inhibitor in the set reached MIC in iron-rich conditions when tested at up to 64 µg/ml (Table
4-2). This selectivity is consistent with their expected mechanism of action in inhibition of
MBTS biosynthesis. It also revealed that the analogue modifications did not lead to any observed
unintended off-target effects in Msm.
Notably, the MIC of 0.5–1 µg/ml found for salicyl-AMS (1) against Msm ∆EM-pMbtAtb
is in reasonable agreement with the MIC of ≈0.1-0.5 µg/ml reported previously for Mtb in ironlimiting medium.31, 71, 72 The similarity between the MIC values of salicyl-AMS (1), salicyl-6-NMe-AMS (5a), and salicyl-AMSN (4a) against Msm ∆EM-pMbtAtb is also in reasonable
agreement with the MIC data reported with Mtb.71, 72 Though salicyl-2´-dAMS (2) displayed
reduced activity in both bacterial species, it was much more prominent in Mtb. This might be a
consequence of the longer incubation period of the MIC assay for Mtb, which could lead to some
degradation of the less-stable 2´-deoxynucleoside structure.66, 142
Out results demonstrated no statistically significant difference between the MIC value of
adenine C2-substituent analogues 3a and 3b with salicyl-AMS (1). This contrasts with the initial
report that these analogues are ten times more potent than 1. Similarly, we found salicyl-6-N-cPr-AMS (5b) to be six times less potent than salicyl-AMS (1), while this analogue was
previously reported to be four times more potent than 1. Of course, previous reports assessed
antimicrobial activity against Mtb, while our assessment measure MIC with the Msm-pMbtAtb
model system. There only appears to be partial agreement about antimicrobial activity between
Msm and Mtb. We cannot ruled out the possibility that in Mtb the increase in potency of
analogues 3a, 3b, and 5b relative to salicyl-AMS (1) is due to an off-target effect not seen with
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Msm. Alternatively, other species-specific factors and/or variations in the experimental
conditions might have contributed to the differences.

Figure 4-3. Representative plots of postantibiotic effect for salicyl-AMS.
The growth vs. time datasets were analyzed to determine the time at which cultures reached an
exponential growth phase threshold of OD600 nm = 0.05 (dotted line). The time-to-threshold data
were used to calculate PAE as the difference between the time-to-threshold values of the
inhibitor-exposed culture and the control cultures. Adapted from [74].
Postantibiotic effect of salicyl-AMS and analogues. We then set out to assess the in
vitro PAE using washout experiments and found that all inhibitors in the set had a considerably
delayed regrowth following exposure to the compounds (Table 4-2). Figure 4-3 shows
representative plots of Msm-pMbtAtb regrowth after one-hour exposure to 5×, 50×, and 100×
MIC concentrations of inhibitor, or the DMSO control. A concentration-dependent PAE trend
was found for the eight inhibitors tested at different concentrations, showing 0–14 h, 12–30 h,
and 19–50 h ranges for the 5×, 50×, and 100× MIC exposures, respectively. Unfortunately, due
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to solubility constraints, inhibitor 6 could only be tested at the 5× concentration but did show a
delayed regrowth as compared to the DMSO control. For reference, drugs commonly used to
treat TB have reported PAEs in the 2–68 h range143 and drugs to treat infections with the fastgrowing Mycobacterium fortuitum have PAEs in the 5–15 h range.144 Within each inhibitor
concentration evaluated, the majority of the PAE values of the analogues had no statistically
significant difference from that of salicyl-AMS (1) (Table 4-2). A correlation between in vitro
PAE and tR datasets has been shown recently,123 and thus we explored this possibility. Pearson
pairwise correlation analysis revealed no significant correlation between the PAE and tR datasets
(PCC < 0.5). This is not surprising considering that the relatively modest tR differences between
the inhibitors (3-fold relative spread) are probably overwhelmed by the various cellular factors
influencing intracellular target engagement (e.g., inhibitor penetration and efflux, target turnover,
etc.),121, 141 If a correlation exists, it is likely that it would have been confounded with such small
differences in tR, and a previous report demonstrating correlation between the parameters had a
larger relative spread among the tR values.123 To our knowledge, these results provide the first
demonstration of PAE for MbtAtb inhibitors. Moreover, they validate Msm ∆EM-pMbtAtb as a
convenient model system for analysis of multiple antimicrobial characteristics of MbtAtb
inhibitors.

Conclusions
The EXO devoid Msm-based model system greatly facilitated our ability to evaluate the
antimicrobial properties of the inhibitors of interest. The strain was engineered to express MbtA
of Mtb to allow for screening of antimicrobial properties against the target of clinical interest.
Additionally, this strain was resistant to salicyl-AMS and analogues in iron-rich medium, ruling
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out the effect of off-target confounders. In contrast, due to the report of activity for these
compounds against Mtb in high iron conditions, such confounders cannot be ruled out.
All of the MbtA inhibitors tested have potent and similar antimycobacterial activity (<10fold difference among the set). This is perhaps not a surprise due to the relatively narrow range
app

of Ki

values (11-fold relative spread) for the compound set. We also demonstrated for the first

time that all the compounds have a substantial PAE, a clinically significant property shared with
drugs commonly used against mycobacterial infections. The PAE and long tR of salicyl-AMS
suggest a retention of the compound at the MbtA target site, a desirable pharmacokinetic
property that increases the value of these inhibitors as potential antibiotics.
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CHAPTER 5: CONCLUDING REMARKS
We have demonstrated a comprehensive analysis of the salicylate adenylation enzyme
MbtA and 9 structurally similar inhibitors with biochemical and antimycobacterial activity. Our
MbtA purification approach successfully increased yield 3-fold. Optimization of the HA-MesG
assay increased MbtA activity 3-fold and allowed for reduction of the input enzyme 4-fold.
These improvements paved the way for the high-throughput analysis of the MbtA inhibitor
kinetics.
We successfully demonstrated kcat and Km values of H10MbtAopt similar to those
previously reported for other recombinant MbtA eznymes, demonstrating the fidelity of the final
enzyme and allowing for its use in the downstream analysis of its inhibition. We successfully
calculated the previously unmeasured intrinsic inhibition constant of MbtA by salicyl-AMS. The
calculated Ki value is consistent with the inhibition of related homologous adenylation enzymes
by salicyl-AMS. Our analyses of salicyl-AMS and the 8 analogues of interest indicate that they
all are potent and competitive TBIs with a static, slow-onset mechanism of inhibition.
As per our kinetic analysis, the inhibitors are relatively similar to one another, with a
considerable tR. The novel salicyl-6-MeO-AMSN (6) analogue is a fairly potent MbtAtb inhibitor,
a property unexpected based on previously published SAR and modeling analyses. These
findings further warrant the exploration of C6-substituents. Additionally, the second novel
analogue, salicyl-AMSNMe (4b), has improved MbtAtb inhibitory potency compared with the
unsubstituted counterpart. This was designed to promote a cisoid conformation favorable for
binding and highlights these substitutions as deserving further investigation.
The EXO devoid Msm-based model system greatly facilitated our ability to evaluate the
antimicrobial properties of the inhibitors of interest. The model was made to heterologously
express MbtAtb, allowing for screening of the inhibitors’ antimicrobial activity against the
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clinically relevant protein target. Additionally, this model was shown to be free of off-target
effect confounders, whereas such confounders cannot be ruled out in SAR analyses of MbtAtb
inhibitors using Mtb, due to antimicrobial activity in high iron conditions.
All of the MbtA inhibitors tested have potent antimycobacterial activity with very similar
app

MIC values (6-fold relative spread), paralleling their relatively narrow range of Ki

values (11-

fold relative spread). Moreover, our experiments demonstrated that all the compounds display a
concentration dependent PAE, a clinically significant property shared with drugs commonly used
against mycobacterial infections. This property, along with the long tR of the inhibitors (3-fold
relative spread), may explain the efficacy of salicyl-AMS monotherapy in the murine model of
TB.31 The PAE and long tR of salicyl-AMS suggest retention of the compound at the target site
during the efficacy studies, which would not be detected in the pharmacokinetic studies where
there are no bacteria to maintain the compound in the lung.
In all, the insights gained in the present study support the advancement of the new
analogues to testing in Mtb strains and set the stage for further preclinical evaluation of
pharmacological and toxicological properties to identify the most promising candidates for
evaluation of in vivo efficacy in macrophage and mouse models of TB.
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APPENDIX: SUPPLEMENTARY TABLES
Table S1. Bacterial strains
Strain

Characteristics

Source or
Reference

Msm mc2155

Wild-type laboratory strain; EXO+ MBT+

126

Msm ΔE

Msm mc2155 with an in-frame, unmarked
MSMG_0019 deletion; EXO– MBT+

This study

Msm ΔM

Msm mc2155 with an in-frame, unmarked mbtA
deletion; EXO+ MBT–

34

Msm ΔEM

Msm mc2155 with an in-frame, unmarked
MSMG_0019 and mbtA deletions; EXO– MBT–

This study

Msm ΔEM-pMbtAtb

Msm ΔEM carrying plasmid pMbtAtb;
EXO– MBT+

This study

Msm ΔEM-pMbtAsm

Msm ΔEM carrying plasmid pMbtAsm;
EXO– MBT+

This study

E. coli DH5α

Strain used for general cloning and subcloning
applications

83

E. coli BL21(DE3)pLysS

Strain used for high-efficiency recombinant
protein overproduction

Thermo Fisher
Scientific Inc.
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Table S2. Plasmids
Plasmid

Characteristics

Source or
Reference

pCR2.1-TOPO

E. coli cloning vector

Thermo Fisher
Scientific Inc.

pET15b

E. coli gene expression vector

MilliporeSigma

pCP0

Mycobacterial expression vector

133

p2NIL

Mycobacterial mutagenesis vector

127

pGOAL19

Mycobacterial mutagenesis vector

127

pH10MbtAopt

pET15b derivative expressing N-terminally
His10-tagged MbtAopt

This study

pH8MbtAopt

pET15b derivative expressing N-terminally
His8-tagged MbtAopt

This study

pH6MbtAopt

pET15b derivative expressing N-terminally
His6-tagged MbtAopt

This study

pMbtAoptH10

pET15b derivative expressing C-terminally
His10-tagged MbtAopt

This study

pMbtAoptH8

pET15b derivative expressing C-terminally
His8-tagged MbtAopt

This study

pMbtAoptH6

pET15b derivative expressing C-terminally
His6-tagged MbtAopt

This study

pH6MbtAoptH6

pET15b derivative expressing C- and N-terminally
His6-tagged MbtAopt

This study

pH8MbtAoptH8

pET15b derivative expressing C- and N-terminally
His8-tagged MbtAopt

This study

pH10MbtAoptH10

pET15b derivative expressing C- and N-terminally
His10-tagged MbtAopt

This study

pH6x2MbtAopt

pET15b derivative expressing MbtAopt with an
N-terminal His6-linker-His6 tag (ref)

This study

pMbtAtb

pCP0 derivative expressing mbtAtb

This study

pMbtAms

pCP0 derivative expressing mbtAms

34

p2NILΔ0019

p2NIL derivative carrying a MSMEG_0019 deletion
cassette

This study

pΔ0019

p2NILΔ0019-pGOAL19; MSMEG_0019 deletion cassettedelivery, suicide plasmid

This study
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Table S3. Oligonucleotides
Name

Sequence (5’ → 3’)

Comments

OF0019

ACTTTGGTCGTCGGATTCCTGCTGGTGCG

IR0019soe

CTATCCAGAAGCCACATCCGCGGTCACGTGC
GAGCGTCC

Primers used for amplification of the 5´
fragment for the MSMEG_0019 deletion
cassette

OR0019

ACATTGGCTTCGCGCCATGGCACCGATTTT

IF0019soe

Primers used for amplification of the 3´
fragment for the MSMEG_0019 deletion
CACGTGACCGCGGATGTGGCTTCTGGATAGTG cassette
GCCGGAA

IF0019

ATCTTCTGAACACGCTCAAGGC

IR0019

AGGTAGTTGAACAGCAGTTGCG

mbtAtbF1

TAGTTAACGAGGAAACCCACATGCCACCGA

mbtAtbR1

TAGCTAGCTCAATGGCAGCGCTGGGTCGTCA

mbtAopt-F

TACCATGGGCATGCCGCCGAAAGCGGCGGAT

Primers used for amplification of internal
segment of MSMEG_0019

Primers used for generation of RBS-mbtAtb
amplicon
mbtAopt amplification; introduction of
5´-end NcoI site

TACCATGGGCAGCAGCCATCATCATCATCAT
mbtAopt-H6F CACAGC

mbtAopt amplification; addition of
N-terminal His6 tag and 5′-end NcoI site

TACCATGGGCAGCAGCCATCATCATCATCAT
mbtAopt-H8F CATCATCACAGCAGCGGCC

mbtAopt amplification; addition of
N-terminal His8 tag and 5´-end NcoI site

TACCATGGGCAGCAGCCATCATCATCATCAT
mbtAopt-H10F CATCATCATCATCACAGCAGCGGCC

mbtAopt amplification; addition of
N-terminal His10 tag and 5´-end NcoI site

mbtAoptH6X2F

mbtAopt-R

TACCATGGGCAGCAGCCATCATCATCATCAT
CACAGCCGTGCGTGGCGTCATCCGCAGTTTG
GCGGTCATCATCATCATCATCACAGCAGCGG
CC

mbtAopt amplification; addition of
N-terminal His6x2 tag and 5´-end NcoI site
mbtAopt amplification; introduction of
3´-end BamHI site

CCGGATCCTTAGTGGCAGCGTTG

CCGGATCCTTAGTGGTGGTGGTGGTGGTGCA
mbtAopt-H6R GGCCGCTGCTGTGGCAGCGTTGGGTGGTAAC
CCGGATCCTTAGTGGTGGTGGTGGTGGTGGT
mbtAopt-H8R GGTGCAGGCCGCTGCTGTGGCAGCGTTGGGT
GGTAAC
CCGGATCCTTAGTGGTGGTGGTGGTGGTGGT
mbtAopt-H10R GGTGGTGGTGCAGGCCGCTGCTGTGGCAGCG
TTGGGTGGTAAC
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mbtAopt amplification; addition of
C-terminal His6 tag and 3´-end BamHI site
mbtAopt amplification; addition of
C-terminal His8 tag and 3´-end BamHI site
mbtAopt amplification; addition of
C-terminal His10 tag and 3´-end BamHI
site

REFERENCES
[1] Gupta, R. S., Lo, B., and Son, J. (2018) Phylogenomics and Comparative Genomic Studies Robustly
Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four
Novel Genera, Frontiers in microbiology 9, 67.
[2] Pfyffer, G. E., and Palicova, F. (2011) Mycobacterium: General Characteristics, Laboratory Detection,
and Staining Procedures, In Manual of Clinical Microbiology, 10th Edition, American Society of
Microbiology.
[3] Forbes, B. A., Hall, G. S., Miller, M. B., Novak, S. M., Rowlinson, M. C., Salfinger, M., Somoskovi,
A., Warshauer, D. M., and Wilson, M. L. (2018) Practice Guidelines for Clinical Microbiology
Laboratories: Mycobacteria, Clinical microbiology reviews 31.
[4] Turenne, C. Y. (2019) Nontuberculous mycobacteria: Insights on taxonomy and evolution, Infection,
genetics and evolution : journal of molecular epidemiology and evolutionary genetics in
infectious diseases 72, 159-168.
[5] Runyon, E. H. (1959) Anonymous mycobacteria in pulmonary disease, The Medical clinics of North
America 43, 273-290.
[6] Tortoli, E. (2014) Microbiological features and clinical relevance of new species of the genus
Mycobacterium, Clinical microbiology reviews 27, 727-752.
[7] Aitken, M. L., Limaye, A., Pottinger, P., Whimbey, E., Goss, C. H., Tonelli, M. R., Cangelosi, G. A.,
Dirac, M. A., Olivier, K. N., Brown-Elliott, B. A., McNulty, S., and Wallace, R. J., Jr. (2012)
Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and
cystic fibrosis center, American journal of respiratory and critical care medicine 185, 231-232.
[8] Bryant, J. M., Grogono, D. M., Greaves, D., Foweraker, J., Roddick, I., Inns, T., Reacher, M.,
Haworth, C. S., Curran, M. D., Harris, S. R., Peacock, S. J., Parkhill, J., and Floto, R. A. (2013)
Whole-genome sequencing to identify transmission of Mycobacterium abscessus between
patients with cystic fibrosis: a retrospective cohort study, Lancet (London, England) 381, 15511560.
[9] Eiglmeier, K., Parkhill, J., Honore, N., Garnier, T., Tekaia, F., Telenti, A., Klatser, P., James, K. D.,
Thomson, N. R., Wheeler, P. R., Churcher, C., Harris, D., Mungall, K., Barrell, B. G., and Cole,
S. T. (2001) The decaying genome of Mycobacterium leprae, Leprosy review 72, 387-398.
[10] Dyer, C. (2010) Tuberculosis, Greenwood Press, Santa Barbara
[11] Chai, Q., Zhang, Y., and Liu, C. H. (2018) Mycobacterium tuberculosis: An Adaptable Pathogen
Associated With Multiple Human Diseases, Frontiers in cellular and infection microbiology 8,
158.
[12] Global tuberculosis report 2018. Geneva: World Health Organization (2018). Licence: CC BYNCSA 3.0 IGO.
[13] Schrager, L. K., Harris, R. C., and Vekemans, J. (2018) Research and development of new
tuberculosis vaccines: a review, F1000Research 7, 1732.
[14] Fogel, N. (2015) Tuberculosis: a disease without boundaries, Tuberculosis (Edinb) 95, 527-531.
[15] Centers for Disease Control and Prevention. (2016) Treatment for TB Disease. Retrieved from
https://www.cdc.gov/tb/topic/treatment/tbdisease.htm
[16] Centers for Disease Control and Prevention. (2017) Drug-Resistant TB. Retrieved from
https://www.cdc.gov/tb/topic/drtb/default.htm
[17] Weinberg, E. D. (1975) Nutritional immunity. Host's attempt to withold iron from microbial
invaders, Jama 231, 39-41.
[18] Hood, M. I., and Skaar, E. P. (2012) Nutritional immunity: transition metals at the pathogen-host
interface, Nature reviews. Microbiology 10, 525-537.
[19] Ratledge, C. (2004) Iron, mycobacteria and tuberculosis, Tuberculosis (Edinb) 84, 110-130.
[20] Cassat, J. E., and Skaar, E. P. (2013) Iron in Infection and Immunity, Cell host & microbe 13, 509519.
94

[21] Sritharan, M. (2016) Iron homeostasis in Mycobacterium tuberculosis: mechanistic insights into
siderophore-mediated iron uptake, Journal of bacteriology.
[22] Golonka, R., Yeoh, B. S., and Vijay-Kumar, M. (2019) The Iron Tug-of-War between Bacterial
Siderophores and Innate Immunity, Journal of innate immunity 11, 249-262.
[23] Tufariello, J. M., Chapman, J. R., Kerantzas, C. A., Wong, K. W., Vilcheze, C., Jones, C. M., Cole,
L. E., Tinaztepe, E., Thompson, V., Fenyo, D., Niederweis, M., Ueberheide, B., Philips, J. A.,
and Jacobs, W. R., Jr. (2016) Separable roles for Mycobacterium tuberculosis ESX-3 effectors in
iron acquisition and virulence, Proc. Natl. Acad. Sci. U S A 113, E348-357.
[24] Holden, V. I., and Bachman, M. A. (2015) Diverging roles of bacterial siderophores during infection,
Metallomics : integrated biometal science 7, 986-995.
[25] Neyrolles, O., Wolschendorf, F., Mitra, A., and Niederweis, M. (2015) Mycobacteria, metals, and the
macrophage, Immunological reviews 264, 249-263.
[26] Hameed, S., Pal, R., and Fatima, Z. (2015) Iron Acquisition Mechanisms: Promising Target Against
Mycobacterium tuberculosis, The open microbiology journal 9, 91-97.
[27] De Voss, J. J., Rutter, K., Schroeder, B. G., and Barry, C. E., 3rd. (1999) Iron acquisition and
metabolism by mycobacteria, J. Bacteriol. 181, 4443-4451.
[28] De Voss, J. J., Rutter, K., Schroeder, B. G., Su, H., Zhu, Y., and Barry, C. E., III. (2000) The
salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for
growth in macrophages, Proc. Natl. Acad. Sci. USA 97, 1252-1257.
[29] Reddy, P. V., Puri, R. V., Chauhan, P., Kar, R., Rohilla, A., Khera, A., and Tyagi, A. K. (2013)
Disruption of mycobactin biosynthesis leads to attenuation of Mycobacterium tuberculosis for
growth and virulence, The Journal of infectious diseases 2013 Jul 9.
[30] Mendum, T. A., Chandran, A., Williams, K., Vordermeier, H. M., Villarreal-Ramos, B., Wu, H.,
Singh, A., Smith, A. A., Butler, R. E., Prasad, A., Bharti, N., Banerjee, R., Kasibhatla, S. M.,
Bhatt, A., Stewart, G. R., and McFadden, J. (2019) Transposon libraries identify novel
Mycobacterium bovis BCG genes involved in the dynamic interactions required for BCG to
persist during in vivo passage in cattle, BMC genomics 20, 431.
[31] Lun, S., Guo, H., Adamson, J., Cisar, J. S., Davis, T. D., Chavadi, S. S., Warren, J. D., Quadri, L. E.,
Tan, D. S., and Bishai, W. R. (2013) Pharmacokinetic and in vivo efficacy studies of the
mycobactin biosynthesis inhibitor salicyl-AMS in mice, Antimicrobial agents and chemotherapy
57, 5138-5140.
[32] Barclay, R., and Ratledge, C. (1986) Metal analogues of mycobactin and exochelin fail to act as
effective antimycobacterial agents, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene.
Series A, Medical microbiology, infectious diseases, virology, parasitology 262, 203-207.
[33] Fang, Z., Sampson, S. L., Warren, R. M., Gey van Pittius, N. C., and Newton-Foot, M. (2015) Iron
acquisition strategies in mycobacteria, Tuberculosis (Edinb) 95, 123-130.
[34] Chavadi, S. S., Stirrett, K. L., Edupuganti, U. R., Sadhanandan, G., Vergnolle, O., Schumacher, E.,
Martin, C., Qiu, W. G., Soll, C. E., and Quadri, L. E. N. (2011) Mutational and phylogenetic
analyses of the mycobacterial mbt gene cluster, J. Bacteriol. 193, 5905-5913.
[35] Quadri, L. E., Sello, J., Keating, T. A., Weinreb, P. H., and Walsh, C. T. (1998) Identification of a
Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the
virulence-conferring siderophore mycobactin, Chem. Biol. 5, 631-645.
[36] Krithika, R., Marathe, U., Saxena, P., Ansari, M. Z., Mohanty, D., and Gokhale, R. S. (2006) A
genetic locus required for iron acquisition in Mycobacterium tuberculosis, Proc Natl Acad Sci U
S A 103, 2069-2074.
[37] Zwahlen, J., Kolappan, S., Zhou, R., Kisker, C., and Tonge, P. J. (2007) Structure and mechanism of
MbtI, the salicylate synthase from Mycobacterium tuberculosis, Biochemistry 46, 954-964.
[38] Rodriguez, G. M., Voskuil, M. I., Gold, B., Schoolnik, G. K., and Smith, I. (2002) ideR, An essential
gene in mycobacterium tuberculosis: role of IdeR in iron-dependent gene expression, iron
metabolism, and oxidative stress response, Infection and immunity 70, 3371-3381.
95

[39] Vergnolle, O., Xu, H., Tufariello, J. M., Favrot, L., Malek, A. A., Jacobs, W. R., Jr., and Blanchard,
J. S. (2016) Post-translational acetylation of MbtA modulates mycobacterial siderophore
biosynthesis, J Biol Chem 291, 22315-22326.
[40] McMahon, M. D., Rush, J. S., and Thomas, M. G. (2012) Analyses of MbtB, MbtE, and MbtF
suggest revisions to the mycobactin biosynthesis pathway in Mycobacterium tuberculosis, J
Bacteriol 194, 2809-2818.
[41] Quadri, L. E. (2014) Biosynthesis of mycobacterial lipids by polyketide synthases and beyond,
Critical reviews in biochemistry and molecular biology 49, 179-211.
[42] Frankel, B. A., and Blanchard, J. S. (2008) Mechanistic analysis of Mycobacterium tuberculosis
Rv1347c, a lysine Nepsilon-acyltransferase involved in mycobactin biosynthesis, Arch Biochem
Biophys 477, 259-266.
[43] Wells, R. M., Jones, C. M., Xi, Z., Speer, A., Danilchanka, O., Doornbos, K. S., Sun, P., Wu, F.,
Tian, C., and Niederweis, M. (2013) Discovery of a siderophore export system essential for
virulence of Mycobacterium tuberculosis, PLoS pathogens 9, e1003120.
[44] Rodriguez, G. M., and Smith, I. (2006) Identification of an ABC transporter required for iron
acquisition and virulence in Mycobacterium tuberculosis, J. Bacteriol. 188, 424-430.
[45] Ates, L. S., Houben, E. N., and Bitter, W. (2016) Type VII Secretion: A Highly Versatile Secretion
System, Microbiology spectrum 4.
[46] Siegrist, M. S., Steigedal, M., Ahmad, R., Mehra, A., Dragset, M. S., Schuster, B. M., Philips, J. A.,
Carr, S. A., and Rubin, E. J. (2014) Mycobacterial Esx-3 requires multiple components for iron
acquisition, mBio 5, e01073-01014.
[47] Siegrist, M. S., Unnikrishnan, M., McConnell, M. J., Borowsky, M., Cheng, T. Y., Siddiqi, N.,
Fortune, S. M., Moody, D. B., and Rubin, E. J. (2009) Mycobacterial Esx-3 is required for
mycobactin-mediated iron acquisition, Proc Natl Acad Sci U S A 106, 18792-18797.
[48] Newton-Foot, M., Warren, R. M., Sampson, S. L., van Helden, P. D., and Gey van Pittius, N. C.
(2016) The plasmid-mediated evolution of the mycobacterial ESX (Type VII) secretion systems,
BMC evolutionary biology 16, 62.
[49] Simeone, R., Bottai, D., Frigui, W., Majlessi, L., and Brosch, R. (2015) ESX/type VII secretion
systems of mycobacteria: Insights into evolution, pathogenicity and protection, Tuberculosis
(Edinb) 95 Suppl 1, S150-154.
[50] Prados-Rosales, R., Baena, A., Martinez, L. R., Luque-Garcia, J., Kalscheuer, R., Veeraraghavan, U.,
Camara, C., Nosanchuk, J. D., Besra, G. S., Chen, B., Jimenez, J., Glatman-Freedman, A.,
Jacobs, W. R., Jr., Porcelli, S. A., and Casadevall, A. (2011) Mycobacteria release active
membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice, The
Journal of clinical investigation 121, 1471-1483.
[51] Lee, J., Kim, S. H., Choi, D. S., Lee, J. S., Kim, D. K., Go, G., Park, S. M., Kim, S. H., Shin, J. H.,
Chang, C. L., and Gho, Y. S. (2015) Proteomic analysis of extracellular vesicles derived from
Mycobacterium tuberculosis, Proteomics 15, 3331-3337.
[52] Jones, C. M., and Niederweis, M. (2011) Mycobacterium tuberculosis can utilize heme as an iron
source, J Bacteriol 193, 1767-1770.
[53] Jones, C. M., Wells, R. M., Madduri, A. V., Renfrow, M. B., Ratledge, C., Moody, D. B., and
Niederweis, M. (2014) Self-poisoning of Mycobacterium tuberculosis by interrupting siderophore
recycling, Proc Natl Acad Sci U S A 111, 1945-1950.
[54] Madigan, C. A., Cheng, T. Y., Layre, E., Young, D. C., McConnell, M. J., Debono, C. A., Murry, J.
P., Wei, J. R., Barry, C. E., 3rd, Rodriguez, G. M., Matsunaga, I., Rubin, E. J., and Moody, D. B.
(2012) Lipidomic discovery of deoxysiderophores reveals a revised mycobactin biosynthesis
pathway in Mycobacterium tuberculosis, Proc Natl Acad Sci U S A 109, 1257-1262.
[55] Madigan, C. A., Martinot, A. J., Wei, J. R., Madduri, A., Cheng, T. Y., Young, D. C., Layre, E.,
Murry, J. P., Rubin, E. J., and Moody, D. B. (2015) Lipidomic analysis links mycobactin
synthase K to iron uptake and virulence in M. tuberculosis, PLoS pathogens 11, e1004792.
96

[56] Ferreras, J. A., Gupta, A., Amin, N. D., Basu, A., Sinha, B. N., Worgall, S., Jayaprakash, V., and
Quadri, L. E. (2011) Chemical scaffolds with structural similarities to siderophores of
nonribosomal peptide-polyketide origin as novel antimicrobials against Mycobacterium
tuberculosis and Yersinia pestis, Bioorganic & medicinal chemistry letters 21, 6533-6537.
[57] Stirrett, K. L., Ferreras, J. A., Jayaprakash, V., Sinha, B. N., Ren, T., and Quadri, L. E. (2008) Small
molecules with structural similarities to siderophores as novel antimicrobials against
Mycobacterium tuberculosis and Yersinia pestis, Bioorg. Med. Chem. Lett. 18, 2662-2668.
[58] Nelson, K. M., Salomon, C. E., and Aldrich, C. C. (2012) Total synthesis and biological evaluation
of transvalencin Z, Journal of natural products 75, 1037-1043.
[59] Vasan, M., Neres, J., Williams, J., Wilson, D. J., Teitelbaum, A. M., Remmel, R. P., and Aldrich, C.
C. (2010) Inhibitors of the salicylate synthase (MbtI) from Mycobacterium tuberculosis
discovered by high-throughput screening, ChemMedChem 5, 2079-2087.
[60] Sassetti, C. M., Boyd, D. H., and Rubin, E. J. (2003) Genes required for mycobacterial growth
defined by high density mutagenesis, Mol Microbiol 48, 77-84.
[61] Adilakshmi, T., Ayling, P. D., and Ratledge, C. (2000) Mutational analysis of a role for salicylic acid
in iron metabolism of Mycobacterium smegmatis, J Bacteriol 182, 264-271.
[62] Manos-Turvey, A., Cergol, K. M., Salam, N. K., Bulloch, E. M., Chi, G., Pang, A., Britton, W. J.,
West, N. P., Baker, E. N., Lott, J. S., and Payne, R. J. (2012) Synthesis and evaluation of M.
tuberculosis salicylate synthase (MbtI) inhibitors designed to probe plasticity in the active site,
Organic & biomolecular chemistry 10, 9223-9236.
[63] Chiarelli, L. R., Mori, M., Barlocco, D., Beretta, G., Gelain, A., Pini, E., Porcino, M., Mori, G.,
Stelitano, G., Costantino, L., Lapillo, M., Bonanni, D., Poli, G., Tuccinardi, T., Villa, S., and
Meneghetti, F. (2018) Discovery and development of novel salicylate synthase (MbtI) furanic
inhibitors as antitubercular agents, European journal of medicinal chemistry 155, 754-763.
[64] Ferreras, J. A., Ryu, J. S., Di Lello, F., Tan, D. S., and Quadri, L. E. (2005) Small-molecule
inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis, Nature
chemical biology 1, 29-32.
[65] Somu, R. V., Wilson, D. J., Bennett, E. M., Boshoff, H. I., Celia, L., Beck, B. J., Barry, C. E., 3rd,
and Aldrich, C. C. (2006) Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR
of the glycosyl domain, Journal of medicinal chemistry 49, 7623-7635.
[66] Duckworth, B. P., Nelson, K. M., and Aldrich, C. C. (2012) Adenylating enzymes in Mycobacterium
tuberculosis as drug targets, Current topics in medicinal chemistry 12, 766-796.
[67] Dawadi, S., Boshoff, H. I. M., Park, S. W., Schnappinger, D., and Aldrich, C. C. (2018)
Conformationally Constrained Cinnolinone Nucleoside Analogues as Siderophore Biosynthesis
Inhibitors for Tuberculosis, ACS medicinal chemistry letters 9, 386-391.
[68] Gupte, A., Boshoff, H. I., Wilson, D. J., Neres, J., Labello, N. P., Somu, R. V., Xing, C., Barry, C.
E., and Aldrich, C. C. (2008) Inhibition of siderophore biosynthesis by 2-triazole substituted
analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: antibacterial nucleosides effective against
Mycobacterium tuberculosis, Journal of medicinal chemistry 51, 7495-7507.
[69] Krajczyk, A., Zeidler, J., Januszczyk, P., Dawadi, S., Boshoff, H. I., Barry, C. E., 3rd, Ostrowski, T.,
and Aldrich, C. C. (2016) 2-Aryl-8-aza-3-deazaadenosine analogues of 5'-O-[N(salicyl)sulfamoyl]adenosine: Nucleoside antibiotics that block siderophore biosynthesis in
Mycobacterium tuberculosis, Bioorganic & medicinal chemistry 24, 3133-3143.
[70] Nelson, K. M., Viswanathan, K., Dawadi, S., Duckworth, B. P., Boshoff, H. I., Barry, C. E., 3rd, and
Aldrich, C. C. (2015) Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis
Inhibitors for Mycobacterium tuberculosis, Journal of medicinal chemistry 58, 5459-5475.
[71] Neres, J., Labello, N. P., Somu, R. V., Boshoff, H. I., Wilson, D. J., Vannada, J., Chen, L., Barry, C.
E., 3rd, Bennett, E. M., and Aldrich, C. C. (2008) Inhibition of siderophore biosynthesis in
Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity
relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine, Journal of
medicinal chemistry 51, 5349-5370.
97

[72] Somu, R. V., Boshoff, H., Qiao, C., Bennett, E. M., Barry, C. E., 3rd, and Aldrich, C. C. (2006)
Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of
Mycobacterium tuberculosis, Journal of medicinal chemistry 49, 31-34.
[73] Vannada, J., Bennett, E. M., Wilson, D. J., Boshoff, H. I., Barry, C. E., 3rd, and Aldrich, C. C. (2006)
Design, synthesis, and biological evaluation of b-ketosulfonamide adenylation inhibitors as
potential antitubercular agents, Org. Lett. 8, 4707-4710.
[74] Bythrow, G. V., Mohandas, P., Guney, T., Standke, L. C., Germain, G. A., Lu, X., Ji, C.,
Levendosky, K., Chavadi, S. S., Tan, D. S., and Quadri, L. E. N. (2019) Kinetic Analyses of the
Siderophore Biosynthesis Inhibitor Salicyl-AMS and Analogues as MbtA Inhibitors and
Antimycobacterial Agents, Biochemistry 58, 833-847.
[75] Lee, J., and Kim, S. H. (2009) High-throughput T7 LIC vector for introducing C-terminal polyhistidine tags with variable lengths without extra sequences, Protein expression and purification
63, 58-61.
[76] Khan, F., He, M., and Taussig, M. J. (2006) Double-hexahistidine tag with high-affinity binding for
protein immobilization, purification, and detection on ni-nitrilotriacetic acid surfaces, Analytical
chemistry 78, 3072-3079.
[77] Robinson, C. R., and Sauer, R. T. (1998) Optimizing the stability of single-chain proteins by linker
length and composition mutagenesis, Proceedings of the National Academy of Sciences 95, 59295934.
[78] Gustafsson, C., Govindarajan, S., and Minshull, J. (2004) Codon bias and heterologous protein
expression, Trends in biotechnology 22, 346-353.
[79] Novy, R., Drott, D., Yaeger, K., and Mierendorf, R. (2001) Overcoming the codon bias of E. coli for
enhanced protein expression, Vol. 12.
[80] GenScript, I. (2019) OptimumGene™-Codon Optimization.
[81] Copeland, R. A. (2013) Enzyme Reaction Mechanisms, In Evaluation of Enzyme Inhibitors in Drug
Discovery, pp 25-55, John Wiley & Sons, Inc.
[82] Brooks, H. B., Geeganage, S., Kahl, S. D., Montrose, C., Sittampalam, S., Smith, M. C., and
Weidner, J. R. (2004) Basics of Enzymatic Assays for HTS, In Assay Guidance Manual
(Sittampalam, G. S., Coussens, N. P., Brimacombe, K., Grossman, A., Arkin, M., Auld, D.,
Austin, C., Baell, J., Bejcek, B., Caaveiro, J. M. M., Chung, T. D. Y., Dahlin, J. L., Devanaryan,
V., Foley, T. L., Glicksman, M., Hall, M. D., Haas, J. V., Inglese, J., Iversen, P. W., Kahl, S. D.,
Kales, S. C., Lal-Nag, M., Li, Z., McGee, J., McManus, O., Riss, T., Trask, O. J., Jr., Weidner, J.
R., Wildey, M. J., Xia, M., and Xu, X., Eds.), Bethesda (MD).
[83] Sambrook, J., Russell, D. W. (2001) Molecular Cloning: a Laboratory Manual, Third Edition. ed.,
Cold Spring Harbor Pres, Cold Spring Harbor, NY.
[84] GenScript. (2018) OptimumGene-Codon Optimization. Retrieved from
https://www.genscript.com/codon-opt.html
[85] Walker, J. M. (2009) The Protein Protocols Handbook, 3rd ed., Humana Press.
[86] Wilson, D. J., and Aldrich, C. C. (2010) A continuous kinetic assay for adenylation enzyme activity
and inhibition, Analytical biochemistry 404, 56-63.
[87] Davis, T. D., Mohandas, P., Chiriac, M. I., Bythrow, G. V., Quadri, L. E., and Tan, D. S. (2016)
Design, synthesis, and biological evaluation of a-hydroxyacyl-AMS inhibitors of amino acid
adenylation enzymes, Bioorg. Med. Chem. Lett. 26, 5340-5345.
[88] Copeland, R. A. (2013) Tight Binding Inhibition, In Evaluation of Enzyme Inhibitors in Drug
Discovery, pp 245-285, John Wiley & Sons, Inc.
[89] Alonzo, D. A., Magarvey, N. A., and Schmeing, T. M. (2015) Characterization of cereulide
synthetase, a toxin-producing macromolecular machine, PloS one 10, e0128569.
[90] Konno, S., Ishikawa, F., Suzuki, T., Dohmae, N., Burkart, M. D., and Kakeya, H. (2015) Active sitedirected proteomic probes for adenylation domains in nonribosomal peptide synthetases,
Chemical communications (Cambridge, England) 51, 2262-2265.
98

[91] Nusca, T. D., Kim, Y., Maltseva, N., Lee, J. Y., Eschenfeldt, W., Stols, L., Schofield, M. M.,
Scaglione, J. B., Dixon, S. D., Oves-Costales, D., Challis, G. L., Hanna, P. C., Pfleger, B. F.,
Joachimiak, A., and Sherman, D. H. (2012) Functional and structural analysis of the siderophore
synthetase AsbB through reconstitution of the petrobactin biosynthetic pathway from Bacillus
anthracis, J Biol Chem 287, 16058-16072.
[92] Tripathi, A., Schofield, M. M., Chlipala, G. E., Schultz, P. J., Yim, I., Newmister, S. A., Nusca, T.
D., Scaglione, J. B., Hanna, P. C., Tamayo-Castillo, G., and Sherman, D. H. (2014) Baulamycins
A and B, broad-spectrum antibiotics identified as inhibitors of siderophore biosynthesis in
Staphylococcus aureus and Bacillus anthracis, J Am Chem Soc 136, 1579-1586.
[93] Bisswanger, H. (2014) Enzyme assays, Perspectives in Science 1, 41-55.
[94] Quadri, L. E. (2000) Assembly of aryl-capped siderophores by modular peptide synthetases and
polyketide synthases, Mol. Microbiol. 37, 1-12.
[95] Gulick, A. M. (2009) Conformational dynamics in the Acyl-CoA synthetases, adenylation domains
of non-ribosomal peptide synthetases, and firefly luciferase, ACS chemical biology 4, 811-827.
[96] Gehring, A. M., Mori, I., Perry, R. D., and Walsh, C. T. (1998) The nonribosomal peptide synthetase
HMWP2 forms a thiazoline ring during biogenesis of yersiniabactin, an iron-chelating virulence
factor of Yersinia pestis, Biochemistry 37, 11637-11650.
[97] Quadri, L. E., Keating, T. A., Patel, H. M., and Walsh, C. T. (1999) Assembly of the Pseudomonas
aeruginosa nonribosomal peptide siderophore pyochelin: in vitro reconstitution of aryl-4,2-bisthiazoline synthetase activity from PchD, PchE, and PchF, Biochemistry 38, 14941-14954.
[98] Engelhart, C. A., and Aldrich, C. C. (2013) Synthesis of chromone, quinolone, and benzoxazinone
sulfonamide nucleosides as conformationally constrained inhibitors of adenylating enzymes
required for siderophore biosynthesis, The Journal of organic chemistry 78, 7470-7481.
[99] Dawadi, S., Kawamura, S., Rubenstein, A., Remmel, R., and Aldrich, C. C. (2016) Synthesis and
pharmacological evaluation of nucleoside prodrugs designed to target siderophore biosynthesis in
Mycobacterium tuberculosis, Bioorganic & medicinal chemistry 24, 1314-1321.
[100] Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its
implications for lead optimization, Nature reviews. Drug discovery 5, 730-739.
[101] Schuetz, D. A., de Witte, W. E. A., Wong, Y. C., Knasmueller, B., Richter, L., Kokh, D. B., Sadiq,
S. K., Bosma, R., Nederpelt, I., Heitman, L. H., Segala, E., Amaral, M., Guo, D., Andres, D.,
Georgi, V., Stoddart, L. A., Hill, S., Cooke, R. M., De Graaf, C., Leurs, R., Frech, M., Wade, R.
C., de Lange, E. C. M., AP, I. J., Muller-Fahrnow, A., and Ecker, G. F. (2017) Kinetics for Drug
Discovery: an industry-driven effort to target drug residence time, Drug discovery today 22, 896911.
[102] Magotti, P., Ricklin, D., Qu, H., Wu, Y. Q., Kaznessis, Y. N., and Lambris, J. D. (2009) Structurekinetic relationship analysis of the therapeutic complement inhibitor compstatin, Journal of
molecular recognition : JMR 22, 495-505.
[103] Copeland, R. A. (2013) Drug–Target Residence Time, In Evaluation of Enzyme Inhibitors in Drug
Discovery, pp 287-344, John Wiley & Sons, Inc.
[104] Copeland, R. A. (2002) Tight Binding Inhibitors, In Enzymes, pp 305-317, John Wiley & Sons, Inc.
[105] Murphy, D. J. (2004) Determination of accurate KI values for tight-binding enzyme inhibitors: an in
silico study of experimental error and assay design, Analytical biochemistry 327, 61-67.
[106] Sikora, A. L., Wilson, D. J., Aldrich, C. C., and Blanchard, J. S. (2010) Kinetic and Inhibition
Studies of Dihydroxybenzoate-AMP Ligase (EntE) from Escherichia coli, Biochemistry 49, 36483657.
[107] McClerren, A. L., Endsley, S., Bowman, J. L., Andersen, N. H., Guan, Z., Rudolph, J., and Raetz,
C. R. (2005) A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A
biosynthesis with antibiotic activity comparable to ciprofloxacin, Biochemistry 44, 16574-16583.
[108] Morrison, J. F., and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme
inhibitors, Advances in enzymology and related areas of molecular biology 61, 201-301.
99

[109] Copeland, R. A. (2013) Slow Binding Inhibitors, In Evaluation of Enzyme Inhibitors in Drug
Discovery, pp 203-244, John Wiley & Sons, Inc.
[110] Chang, A., Schiebel, J., Yu, W., Bommineni, G. R., Pan, P., Baxter, M. V., Khanna, A., Sotriffer,
C. A., Kisker, C., and Tonge, P. J. (2013) Rational optimization of drug-target residence time:
insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex,
Biochemistry 52, 4217-4228.
[111] Larionova, N. I., Gladysheva, I. P., and Gladyshev, D. P. (1997) Human leukocyte elastase
inhibition by Bowman-Birk soybean inhibitor. Discrimination of the inhibition mechanisms,
FEBS letters 404, 245-248.
[112] May, J. J., Kessler, N., Marahiel, M. A., and Stubbs, M. T. (2002) Crystal structure of DhbE, an
archetype for aryl acid activating domains of modular nonribosomal peptide synthetases, Proc
Natl Acad Sci U S A 99, 12120-12125.
[113] Cisar, J. S., Ferreras, J. A., Soni, R. K., Quadri, L. E., and Tan, D. S. (2007) Exploiting ligand
conformation in selective inhibition of non-ribosomal peptide synthetase amino acid adenylation
with designed macrocyclic small molecules, Journal of the American Chemical Society 129,
7752-7753.
[114] Tawari, N. R., and Degani, M. S. (2011) Predictive models for nucleoside bisubstrate analogs as
inhibitors of siderophore biosynthesis in Mycobacterium tuberculosis: pharmacophore mapping
and chemometric QSAR study, Molecular diversity 15, 435-444.
[115] Labello, N. P., Bennett, E. M., Ferguson, D. M., and Aldrich, C. C. (2008) Quantitative three
dimensional structure linear interaction energy model of 5'-O-[N-(salicyl)sulfamoyl]adenosine
and the aryl acid adenylating enzyme MbtA, Journal of medicinal chemistry 51, 7154-7160.
[116] Maganti, L., Open Source Drug Discovery, C., and Ghoshal, N. (2014) Probing the structure of
Mycobacterium tuberculosis MbtA: model validation using molecular dynamics simulations and
docking studies, J. Biomol. Struct. Dyn. 32, 273-288.
[117] Tummino, P. J., and Copeland, R. A. (2008) Residence time of receptor-ligand complexes and its
effect on biological function, Biochemistry 47, 5481-5492.
[118] Nunez, S., Venhorst, J., and Kruse, C. G. (2012) Target-drug interactions: First principles and their
application to drug discovery, Drug Discov. Today 17, 10-22.
[119] Quadri, L. E. (2007) Strategic paradigm shifts in the antimicrobial drug discovery process of the
21st century, Infect. Disord. Drug Targets 7, 230-237.
[120] Craig, W. A. (2007) Pharmacodynamics of antimicrobials: General concepts and applications, In
Antimicrobial pharmacodynamics in theory and clinical practice (Nightingale, C. H., Ambrose,
P. G., Drusano, G. L., and Murakawa, T., Eds.) 2nd ed., pp 1-22, Informa Healthcare USA, Inc.,
New York, NY.
[121] Tonge, P. J. (2018) Drug-Target Kinetics in Drug Discovery, ACS chemical neuroscience 9, 29-39.
[122] MacKenzie, F. M., and Gould, I. M. (1993) The post-antibiotic effect, The Journal of antimicrobial
chemotherapy 32, 519-537.
[123] Walkup, G. K., You, Z., Ross, P. L., Allen, E. K., Daryaee, F., Hale, M. R., O'Donnell, J., Ehmann,
D. E., Schuck, V. J., Buurman, E. T., Choy, A. L., Hajec, L., Murphy-Benenato, K., Marone, V.,
Patey, S. A., Grosser, L. A., Johnstone, M., Walker, S. G., Tonge, P. J., and Fisher, S. L. (2015)
Translating slow-binding inhibition kinetics into cellular and in vivo effects, Nature chemical
biology 11, 416-423.
[124] Ratledge, C., and Ewing, M. (1996) The occurrence of carboxymycobactin, the siderophore of
pathogenic mycobacteria, as a second extracellular siderophore in Mycobacterium smegmatis,
Microbiology 142 ( Pt 8), 2207-2212.
[125] Sharman, G. J., Williams, D. H., Ewing, D. F., and Ratledge, C. (1995a) Isolation, purification and
structure of exochelin MS, the extracellular siderophore from Mycobacterium smegmatis, The
Biochemical journal 305, 187-196.

100

[126] Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., and Jacobs, W. R., Jr. (1990) Isolation and
characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis, Mol
Microbiol 4, 1911-1919.
[127] Parish, T., and Stoker, N. G. (2000) Use of a flexible cassette method to generate a double
unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement, Microbiology
146, 1969-1975.
[128] Mohan, A., Padiadpu, J., Baloni, P., and Chandra, N. (2015) Complete genome sequences of a
Mycobacterium smegmatis laboratory strain (MC2 155) and isoniazid-resistant (4XR1/R2) mutant
strains, Genome announcements 3.
[129] Fiss, E. H., Yu, S., and Jacobs, W. R., Jr. (1994) Identification of genes involved in the
sequestration of iron in mycobacteria: the ferric exochelin biosynthetic and uptake pathways,
Mol. Microbiol. 14, 557-569.
[130] Yu, S., Fiss, E., and Jacobs, W. R., Jr. (1998) Analysis of the exochelin locus in Mycobacterium
smegmatis: biosynthesis genes have homology with genes of the peptide synthetase family, J
Bacteriol 180, 4676-4685.
[131] Zhu, W., Arceneaux, J. E., Beggs, M. L., Byers, B. R., Eisenach, K. D., and Lundrigan, M. D.
(1998) Exochelin genes in Mycobacterium smegmatis: identification of an ABC transporter and
two non-ribosomal peptide synthetase genes, Mol Microbiol 29, 629-639.
[132] Ma, J., Campbell, A., and Karlin, S. (2002) Correlations between Shine-Dalgarno sequences and
gene features such as predicted expression levels and operon structures, J Bacteriol 184, 57335745.
[133] Ferreras, J. A., Stirrett, K. L., Lu, X., Ryu, J. S., Soll, C. E., Tan, D. S., and Quadri, L. E. (2008)
Mycobacterial phenolic glycolipid virulence factor biosynthesis: Mechanism and small-molecule
inhibition of polyketide chain initiation, Chem. Biol. 15, 51-61.
[134] Chan, C. Y., Au-Yeang, C., Yew, W. W., Leung, C. C., and Cheng, A. F. (2004) In vitro
postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium
tuberculosis, Antimicrobial agents and chemotherapy 48, 340-343.
[135] Stubbings, W. J., Bostock, J. M., Ingham, E., and Chopra, I. (2004) Assessment of a microplate
method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coli,
The Journal of antimicrobial chemotherapy 54, 139-143.
[136] Schwyn, B., and Neilands, J. B. (1987) Universal chemical assay for the detection and
determination of siderophores, Analytical biochemistry 160, 47-56.
[137] Ames-Gottfred, N. P., Christie, B. R., and Jordan, D. C. (1989) Use of the Chrome Azurol S Agar
Plate Technique To Differentiate Strains and Field Isolates of Rhizobium leguminosarum biovar
trifolii, Appl Environ Microbiol 55, 707-710.
[138] Alexander, D. B., and Zuberer, D. A. (1991) Use of chrome azurol S reagents to evaluate
siderophore production by rhizosphere bacteria, Biology and Fertility of Soils 12, 39-45.
[139] Rodrigues, L., Villellas, C., Bailo, R., Viveiros, M., and Ainsa, J. A. (2013) Role of the Mmr efflux
pump in drug resistance in Mycobacterium tuberculosis, Antimicrobial agents and chemotherapy
57, 751-757.
[140] Carson, L. A., Cusick, L. B., Bland, L. A., and Favero, M. S. (1988) Efficacy of chemical dosing
methods for isolating nontuberculous mycobacteria from water supplies of dialysis centers, Appl
Environ Microbiol 54, 1756-1760.
[141] Davis, T. D., Gerry, C. J., and Tan, D. S. (2014) General platform for systematic quantitative
evaluation of small-molecule permeability in bacteria, ACS chemical biology 9, 2535-2544.
[142] Lindahl, T. (1993) Instability and decay of the primary structure of DNA, Nature 362, 709-715.
[143] Chan, C. Y., Au-Yeang, C., Yew, W. W., Hui, M., and Cheng, A. F. (2001) Postantibiotic effects of
antituberculosis agents alone and in combination, Antimicrob. Agents Chemother. 45, 3631-3634.
[144] Tsui, S. Y., Yew, W. W., Li, M. S., Chan, C. Y., and Cheng, A. F. (1993) Postantibiotic effects of
amikacin and ofloxacin on Mycobacterium fortuitum, Antimicrob. Agents Chemother. 37, 10011003.
101

